Bristol Myers Squibb uvedla, že její experimentální buněčná terapie arlocabtagene autoleucel (arlo-cel) ve středně pokročilé studii splnila hlavní cíl u pacientů s pokročilým mnohočetným myelomem, kteří již vyzkoušeli čtyři hlavní třídy standardní léčby bez trvalého úspěchu. U části pacientů také zcela odstranila zjistitelné známky rakoviny.
Bristol Myers Squibb (BMY.N) said on Tuesday its experimental cell therapy showed a high overall response rate in a mid-stage trial, in patients with a hard-to-treat form of blood cancer.
The study evaluated the therapy, called arlocabtagene autoleucel, or arlo-cel, in patients with advanced multiple myeloma who had already tried four major classes of standard treatments without lasting success.
Bristol Myers said the trial met its main goal by showing a meaningful improvement in the overall response rate among patients who had exhausted standard therapies.
It also met a key secondary goal, completely clearing detectable signs of the cancer in some patients.
While the drugmaker did not release specific numerical data, it said the results were statistically significant and clinically meaningful and that full findings will be presented at an upcoming medical meeting.
Arlo-cel is a CAR-T cell therapy administered as a single infusion. The personalized treatment works by extracting a patient's own immune cells, modifying them in a laboratory to target a specific protein on cancer cells called GPRC5D and infusing them back into the body to attack the disease.
The therapy's safety profile was consistent with expectations and in line with other CAR-T and GPRC5D-targeting therapies, the company said.
Multiple myeloma is a cancer that forms in plasma cells, a type of white blood cell.
An estimated 36,000 new cases and nearly 11,000 deaths from the disease are expected in the United States this year, according to the American Cancer Society.
Key Takeaways Bristol Myers Squibb's Camzyos showed durable reductions in LVOT obstruction at five years.Camzyos sales surged 74% year over year to $729 million in the first half of 2026.BMY could expand Camzyos to adolescents, with an FDA decision targeted for Sept. 30, 2026. Bristol Myers Squibb’s (BMY - Free Report) latest Camzyos (mavacamten) data strengthen the investment case for the drug as a durable growth driver in cardiovascular care.
The company recently presented positive results from the EXPLORER-LTE cohort of the MAVA-LTE study on Camzyos in a late-breaker presentation at the European Society of Cardiology (“ESC”) Congress 2026.
The drug is currently approved in the United States for adults with symptomatic New York Heart Association (“NYHA”) class II-III obstructive hypertrophic cardiomyopathy (oHCM) to improve symptoms and functional capacity.
Five-year results from the EXPLORER-LTE cohort showed that Camzyos continued to deliver meaningful reductions in left ventricular outflow tract (LVOT) obstruction and improvements in symptoms and functional status in patients with symptomatic oHCM.
EXPLORER-LTE is a single-arm, open-label, dose-blinded extension of the phase III EXPLORER-HCM study evaluating the long-term safety and efficacy of Camzyos.
At 252 weeks, Camzyos reduced resting and Valsalva left ventricular outflow tract (LVOT) gradients by 38.7 mm Hg and 55.6 mm Hg, respectively. Nearly 97.4% of patients achieved a Valsalva LVOT gradient of ≤30 mm Hg, while 69.6% improved by at least one NYHA class and 59.2% became asymptomatic. No new safety signals emerged.
The real-world data presented at ESC 2026 further reinforce Camzyos’ effectiveness and safety, suggesting that the benefits observed in clinical trials are translating into routine clinical practice.
With approval in more than 60 countries, Camzyos has established a strong competitive position in the cardiac myosin inhibitor market.
The five-year durability and growing real-world evidence are encouraging for sustained demand and continued revenue contributions from Camzyos, helping BMY diversify beyond its legacy products.
Sales of Camzyos surged 74% year over year to $729 million in the first half of 2026, underscoring the drug’s growing contribution to Bristol Myers Squibb’s cardiovascular franchise and its potential to remain an important growth driver for the company.
Adding to the growth opportunity, the FDA accepted BMY’s supplemental new drug application in June 2026 seeking approval of Camzyos for adolescents aged 12 to under 18 years with symptomatic oHCM. The agency granted Priority Review, with a target action date of Sept. 30, 2026, creating a near-term regulatory catalyst for investors.
The sNDA is supported by data from the late-stage SCOUT-HCM study. If approved, Camzyos would become the first cardiac myosin inhibitor available for adolescents with oHCM, giving BMY an opportunity to expand the drug’s addressable patient population beyond adults.
The growing pipeline of next-generation cardiovascular therapies highlights the need for Camzyos to maintain strong efficacy, safety, market penetration and long-term patient retention as competition intensifies.
BMY’s cardiovascular portfolio also includes blood thinner medicine Eliquis, for which BMY has a worldwide co-development and co-commercialization agreement with pharma giant Pfizer. Eliquis remains one of the biggest contributors to the company’s top line.
BMY’s cardiovascular pipeline includes milvexian, an investigational oral, highly selective factor XIa inhibitor.
Competition for BMY’s CamzyosCytokinetics (CYTK - Free Report) became a direct competitor to Bristol Myers Squibb in oHCM market after securing FDA approval for Myqorzo (aficamten) in December 2025. As Cytokinetics’ first approved product, Myqorzo marks its transition to a commercial-stage company and gives investors a new challenger in the cardiac myosin inhibitor market.
While Camzyos benefits from an established commercial presence and extensive clinical and real-world data, Myqorzo’s initial uptake has been encouraging and could gradually increase competitive pressure on BMY’s cardiovascular franchise.
CYTK is also looking to expand Myqorzo’s label. Cytokinetics plans to submit a sNDA seeking approval of aficamten in symptomatic non-obstructive hypertrophic cardiomyopathy in the fourth quarter of 2026. A potential approval in nHCM will expand the addressable market.
A potential competitor is Edgewise Therapeutics, Inc. (EWTX - Free Report) , which is advancing a cardiovascular pipeline targeting HCM, heart failure, and other cardiovascular and cardiometabolic conditions.
EWTX’s lead candidate, EDG-7500, is a novel, oral, selective cardiac sarcomere modulator currently being studied in a multi-part phase II study in patients with oHCM and nHCM, with a phase III program targeted to be launched in the fourth quarter of 2026.
EWTX’s pipeline also includes EDG-15400 for heart failure. The company expects to initiate a phase II study on EDG-15400 in participants with heart failure with preserved ejection fraction in the second half of 2026.
BMY’s Price Performance, Valuation & EstimatesShares of Bristol Myers have gained 20.3% year to date compared with the industry’s 12.2% growth.
Image Source: Zacks Investment Research
From a valuation standpoint, BMY trades at a discount to the large-cap pharma industry. Going by the price/earnings ratio, its shares currently trade at 10.35X forward earnings, higher than its mean of 8.67X but lower than the large-cap pharma industry’s 18.95X.
Image Source: Zacks Investment Research
The Zacks Consensus Estimate for 2026 EPS has moved north to $6.86 from $6.32 over the past 30 days, while that for 2027 EPS has inched up to $6.44 from $6.09 in the same time frame.
Bristol Myers Squibb ukončila partnerství s Cellares na výrobu CAR-T terapie Breyanzi, protože platforma Cell Shuttle nesplnila požadavky pro komerční škálování. Cellares zároveň oznámila zhruba 100 propouštění.
Bristol Myers Squibb (BMY.N) has ended its partnership with cell therapy startup Cellares that aimed to expand the manufacturing of its personalized blood cancer therapy, a company spokesperson told Reuters on Tuesday.
Bristol Myers determined that Cellares' cell therapy manufacturing platform, Cell Shuttle, could not meet the requirements to make its CAR-T therapy, Breyanzi, at commercial scale, the spokesperson said.
Cellares strongly disagrees with this characterization, the company told Reuters. The Cell Shuttle platform has already manufactured a Good Manufacturing Practice-compliant cell therapy product in an FDA-regulated clinical program, it said.
Personalized CAR-T therapies have transformed care for some blood cancer patients, but remain difficult and expensive to produce.
Breyanzi, first approved by the U.S. FDA in 2021, is used to treat lymphoma and other blood cancers. It generated $1.36 billion in sales in 2025.
Endpoints News first reported the development on Tuesday.
CELLARES TO CUT 100 JOBS
Cellares CEO Fabian Gerlinghaus had disclosed the loss of a "large pharmaceutical customer" in a LinkedIn post over the weekend, adding that this would force the company to "resize" its workforce.
The startup will lay off about 100 employees at its South San Francisco facility on October 20, according to a notice filed with the California Employment Development Department on August 21. It will give affected workers at least 60 days' notice and full salary and benefits until October 20.
The notice did not mention severance packages.
Cellares did not respond to a Reuters request for comment on the layoffs.
The companies signed a deal in 2024 worth up to $380 million under which Bristol Myers reserved manufacturing capacity across the U.S., the European Union and Japan for CAR-T therapies.
Bristol Myers' decision only applies to Breyanzi and its approved manufacturing process.
CAR-T therapies work by removing a patient's immune cells, reprogramming them in a lab to fight cancer and infusing them back into the body.
Camzyos zvýšil tržby v 1. pololetí 2026 o 74 % na 729 mil. USD a FDA mu udělil Priority Review pro použití u dospívajících ve věku 12 až méně než 18 let se symptomatickou oHCM.
Key Takeaways Bristol Myers sees Camzyos sales soar 74% to $729 million in the first half of 2026.Camzyos won Priority Review for use in adolescents with symptomatic oHCM, with a Sept. 30 FDA date.Cytokinetics and Edgewise are advancing competing cardiovascular drugs targeting oHCM and other conditions. Bristol Myers Squibb (BMY - Free Report) is banking on label expansion of existing drugs and approval of new drugs to further propel its growth portfolio.
Camzyos (mavacamten) is one of the key drugs of this product portfolio. The drug is currently approved in the United States for adults with symptomatic New York Heart Association (“NYHA”) class II-III obstructive hypertrophic cardiomyopathy (oHCM) to improve symptoms and functional capacity.
The drug continued to gain traction in the targeted market in the first half of 2026, supported by growing demand and increased adoption among eligible patients. Sales of the drug surged 74% year over year to $729 million in the first half.
In June 2026, the FDA accepted BMY’s supplemental new drug application (sNDA) seeking approval of Camzyos for the treatment of adolescents aged 12 to under 18 years with symptomatic oHCM.
The FDA granted Priority Review to the application with a target action date of Sept. 30, 2026.
The sNDA submission was based on data from the late-stage SCOUT-HCM study.
If approved, Camzyos would become the first cardiac myosin inhibitor available for adolescents with oHCM and expand the drug's addressable market beyond adults.
For Bristol Myers, continued growth from Camzyos is particularly important as the company works to offset revenue pressures from patent expirations affecting legacy drugs.
BMY’s cardiovascular portfolio also includes blood thinner medicine Eliquis, for which BMY has a worldwide co-development and co-commercialization agreement with pharma giant Pfizer. Eliquis remains one of the biggest contributors to the company’s top line.
BMY’s cardiovascular pipeline includes milvexian, an investigational oral, highly selective factor XIa (FXIa) inhibitor.
The candidate is being evaluated in two late-stage studies — Librexia AF for atrial fibrillation (AF) and Librexia STROKE for secondary stroke prevention (SSP). Data from the Librexia AF study are now expected in the first quarter of 2027.
Management noted that the study is event-driven and that the revised late-2026 timeline reflects the pace of events.
Data from the LIBREXIA-STROKE study are expected in 2026.
BMY’s cardiovascular portfolio suffered a setback in late 2025 after the company decided to discontinue the late-stage Librexia study on milvexian.
BMY and partner Johnson & Johnson were evaluating the efficacy and safety of milvexian when added to standard of care (conventional antiplatelet therapy) for patients following an acute coronary syndrome event.
Both companies decided to discontinue the phase III Librexia ACS study following a preplanned interim analysis by the Independent Data Monitoring Committee, which determined that the study was unlikely to meet its primary efficacy endpoint.
Competition for BMY’s Cardiovascular DrugsIn December 2025, Cytokinetics (CYTK - Free Report) obtained FDA approval for aficamten for the treatment of patients with obstructive HCM in the United States, under the brand name Myqorzo.
This marks the company’s first FDA-approved product, transforming Cytokinetics from a development-stage biotech into a commercial-stage company.
The approval of Myqorzo is a significant boost for CYTK, given the market potential for the oHCM market. The initial uptake has been strong.
Edgewise Therapeutics, Inc. (EWTX - Free Report) is advancing a cardiovascular pipeline targeting HCM, heart failure, and other cardiovascular and cardiometabolic conditions.
EWTX’s lead candidate, EDG-7500, is a novel, oral, selective cardiac sarcomere modulator currently being studied in a multipart phase II study in patients with obstructive HCM and nonobstructive HCM, with a phase III program targeted to initiate in the fourth quarter of 2026.
EWTX’s pipeline also includes EDG-15400 for heart failure. The company expects to initiate a phase II study on EDG-15400 in participants with heart failure with preserved ejection fraction in the second half of 2026.
BMY’s Price Performance, Valuation & EstimatesShares of Bristol Myers have gained 25.3% year to date compared with the industry’s 12.6% growth.
Image Source: Zacks Investment Research
From a valuation standpoint, BMY trades at a discount to the large-cap pharma industry. Going by the price/earnings ratio, its shares currently trade at 10.26X forward earnings, higher than its mean of 8.64X but lower than the large-cap pharma industry’s 19.53X.
Image Source: Zacks Investment Research
The Zacks Consensus Estimate for 2026 EPS has moved north to $6.86 from $6.34 over the past 30 days, while that for 2027 EPS has inched up to $6.44 from $6.12 in the same time frame.
Ancora Advisors LLC ve 2. čtvrtletí nově nakoupila 24 068 akcií Bristol Myers Squibb za zhruba 1,387 milionu USD. FDA mezitím schválila Zenbexus pro dospělé s relabujícím nebo refrakterním mnohočetným myelomem.
Ancora Advisors LLC purchased a new position in shares of Bristol Myers Squibb Company (NYSE:BMY – Free Report) in the 2nd quarter, according to the company in its most recent filing with the Securities and Exchange Commission (SEC). The institutional investor purchased 24,068 shares of the biopharmaceutical company’s stock, valued at approximately $1,387,000.
A number of other institutional investors and hedge funds have also bought and sold shares of the stock. Primecap Management Co. CA bought a new position in Bristol Myers Squibb during the 2nd quarter valued at $1,436,115,000. Canada Pension Plan Investment Board purchased a new stake in shares of Bristol Myers Squibb in the second quarter valued at about $241,223,000. Legal & General Group Plc bought a new position in shares of Bristol Myers Squibb during the second quarter valued at about $980,862,000. The Manufacturers Life Insurance Company purchased a new position in Bristol Myers Squibb during the second quarter worth about $125,419,000. Finally, Van Hulzen Asset Management LLC bought a new stake in Bristol Myers Squibb in the 2nd quarter worth about $975,000. 76.41% of the stock is owned by hedge funds and other institutional investors.
Key Headlines Impacting Bristol Myers Squibb Here are the key news stories impacting Bristol Myers Squibb this week:
Positive Sentiment: The FDA approved Zenbexus (iberdomide), BMY’s first-in-class CELMoD therapy, for adults with relapsed or refractory multiple myeloma in combination with Darzalex and dexamethasone. The approval adds a potential oncology growth driver and expands BMY’s treatment portfolio in a major cancer market. New FDA Approval Gives Bristol-Myers Squibb Another Potential Oncology Growth Catalyst Positive Sentiment: Zenbexus received accelerated approval based on improved minimal residual disease-negative complete response rates. As the first approved CELMoD therapy in this setting, it could strengthen BMY’s competitive position in multiple myeloma, although continued approval depends on confirmatory evidence. Zenbexus First-in-Class CELMoD Approval Positive Sentiment: BMY is extending clinical development of deucravacitinib, signaling longer-term ambitions in autoimmune diseases and potentially broadening its growth pipeline beyond oncology. Bristol Myers Squibb Extends Deucravacitinib Program Neutral Sentiment: Camzyos continues to gain momentum, but its ability to offset patent pressures on older products depends partly on an upcoming FDA decision regarding adolescent use and competition from rival heart drugs. Can Camzyos Growth Offset Bristol Myers Patent Pressures? Negative Sentiment: BMY ended its Cellares partnership after concluding that the Cell Shuttle platform could not support commercial-scale manufacturing of Breyanzi. The decision raises questions about manufacturing capacity and the pace of Breyanzi growth, despite avoiding further spending under the agreement valued at up to $380 million. Bristol-Myers Squibb’s Cellares Exit Raises Questions Over Breyanzi Growth Negative Sentiment: Senior Vice President Phil Holzer sold 500 BMY shares for approximately $33,750, reducing his holdings by 2.88%. The small transaction is generally a limited signal, but may add modest caution after the stock’s recent advance. Bristol Myers Squibb SVP Sells 500 Shares Negative Sentiment: A patent dispute involving Cytokinetics creates additional legal uncertainty around BMY’s products and could increase future litigation or commercial risks. What Does Bristol Myers Squibb Face After Zenbexus Approval and Patent Action? Wall Street Analysts Forecast Growth Several research firms have commented on BMY. Jefferies Financial Group lowered shares of Bristol Myers Squibb from a “buy” rating to a “hold” rating in a research note on Wednesday, August 5th. Bank of America reduced their target price on Bristol Myers Squibb from $67.00 to $66.00 and set a “buy” rating for the company in a report on Friday, July 10th. BMO Capital Markets reaffirmed a “market perform” rating on shares of Bristol Myers Squibb in a research report on Monday, July 27th. UBS Group lowered Bristol Myers Squibb from a “buy” rating to a “neutral” rating in a report on Wednesday, August 5th. Finally, TD Cowen started coverage on Bristol Myers Squibb in a research report on Wednesday, August 5th. They issued a “buy” rating on the stock. One equities research analyst has rated the stock with a Strong Buy rating, thirteen have given a Buy rating, ten have assigned a Hold rating and one has issued a Sell rating to the company’s stock. According to data from MarketBeat.com, Bristol Myers Squibb has a consensus rating of “Moderate Buy” and an average target price of $66.06. View Our Latest Research Report on BMY
Insider Activity In other Bristol Myers Squibb news, SVP Phil M. Holzer sold 500 shares of the firm’s stock in a transaction dated Tuesday, August 25th. The stock was sold at an average price of $67.50, for a total transaction of $33,750.00. Following the sale, the senior vice president owned 16,862 shares in the company, valued at $1,138,185. This trade represents a 2.88% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the SEC, which is available at this hyperlink. Corporate insiders own 0.05% of the company’s stock.
Bristol Myers Squibb Trading Down 0.9% Shares of BMY opened at $66.93 on Friday. The business’s 50-day moving average price is $61.51 and its 200-day moving average price is $59.64. The company has a quick ratio of 1.38, a current ratio of 1.53 and a debt-to-equity ratio of 1.89. Bristol Myers Squibb Company has a twelve month low of $42.52 and a twelve month high of $68.64. The stock has a market cap of $136.73 billion, a PE ratio of 14.74, a P/E/G ratio of 0.18 and a beta of 0.22.
Bristol Myers Squibb (NYSE:BMY – Get Free Report) last posted its earnings results on Thursday, July 30th. The biopharmaceutical company reported $2.04 earnings per share for the quarter, topping analysts’ consensus estimates of $1.60 by $0.44. The business had revenue of $12.97 billion for the quarter, compared to analyst estimates of $11.74 billion. Bristol Myers Squibb had a net margin of 18.87% and a return on equity of 66.90%. Bristol Myers Squibb’s revenue was up 5.7% on a year-over-year basis. During the same quarter in the prior year, the firm posted $1.46 EPS. Bristol Myers Squibb has set its FY 2026 guidance at 6.750-7.000 EPS. On average, equities analysts forecast that Bristol Myers Squibb Company will post 6.95 EPS for the current fiscal year.
Bristol Myers Squibb Announces Dividend The business also recently declared a quarterly dividend, which was paid on Monday, August 3rd. Stockholders of record on Thursday, July 2nd were issued a $0.63 dividend. The ex-dividend date of this dividend was Thursday, July 2nd. This represents a $2.52 dividend on an annualized basis and a dividend yield of 3.8%. Bristol Myers Squibb’s dividend payout ratio is presently 55.51%.
(Free Report)
Bristol Myers Squibb is a global biopharmaceutical company headquartered in Princeton, New Jersey, focused on discovering, developing and delivering medicines for serious diseases. The company’s core activities include research and development, clinical development, manufacturing and commercialization of prescription pharmaceuticals across multiple therapeutic areas. BMS concentrates on advancing therapies in oncology, hematology, immunology, cardiovascular disease and specialty areas through both small molecules and biologics.
BMS’s marketed portfolio and late‑stage pipeline reflect a strong emphasis on cancer and immune‑mediated conditions.
Recommended Stories Five stocks we like better than Bristol Myers Squibb Nutanix’s Rally Has a Bigger Story Than Earnings as AMD’s AI Bet Takes Shape SEC Probe Puts Wall Street Leverage Risk Back in Focus A Bearish-Dollar Options Surge Raises the Stakes for Warsh at Jackson Hole Five Below’s Turnaround Is Working—But Has the Stock Run Too Far?
Receive News & Ratings for Bristol Myers Squibb Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Bristol Myers Squibb and related companies with MarketBeat.com's FREE daily email newsletter.
Bank OZK ve 2. čtvrtletí koupila nový podíl v Bristol Myers Squibb za zhruba 474 000 USD, konkrétně 8 232 akcií. Firma zároveň oznámila zisk na akcii 2,04 USD a tržby 12,97 miliardy USD, obojí nad odhady.
Bank OZK bought a new stake in shares of Bristol Myers Squibb Company (NYSE:BMY – Free Report) during the second quarter, according to its most recent 13F filing with the SEC. The institutional investor bought 8,232 shares of the biopharmaceutical company’s stock, valued at approximately $474,000.
A number of other institutional investors have also made changes to their positions in the stock. Davis Asset Management L.P. bought a new stake in shares of Bristol Myers Squibb in the 2nd quarter valued at $27,000. Swiss RE Ltd. bought a new stake in Bristol Myers Squibb in the 4th quarter valued at approximately $25,000. Darwin Wealth Management LLC acquired a new position in Bristol Myers Squibb during the second quarter worth $25,000. Addison Advisors LLC bought a new position in shares of Bristol Myers Squibb in the 2nd quarter valued at about $32,000. Finally, Bayban bought a new position in Bristol Myers Squibb in the fourth quarter valued at approximately $31,000. 76.41% of the stock is owned by institutional investors and hedge funds.
Insider Activity at Bristol Myers Squibb In other news, SVP Phil M. Holzer sold 500 shares of the business’s stock in a transaction that occurred on Tuesday, August 25th. The stock was sold at an average price of $67.50, for a total transaction of $33,750.00. Following the completion of the sale, the senior vice president owned 16,862 shares in the company, valued at $1,138,185. The trade was a 2.88% decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the SEC, which is available through this hyperlink. 0.05% of the stock is currently owned by corporate insiders.
Bristol Myers Squibb Trading Down 0.9% BMY opened at $66.93 on Friday. Bristol Myers Squibb Company has a twelve month low of $42.52 and a twelve month high of $68.64. The company has a quick ratio of 1.38, a current ratio of 1.53 and a debt-to-equity ratio of 1.89. The company has a fifty day moving average of $61.51 and a 200-day moving average of $59.64. The stock has a market cap of $136.73 billion, a PE ratio of 14.74, a price-to-earnings-growth ratio of 0.18 and a beta of 0.22. Bristol Myers Squibb (NYSE:BMY – Get Free Report) last issued its earnings results on Thursday, July 30th. The biopharmaceutical company reported $2.04 earnings per share for the quarter, topping analysts’ consensus estimates of $1.60 by $0.44. The business had revenue of $12.97 billion during the quarter, compared to the consensus estimate of $11.74 billion. Bristol Myers Squibb had a return on equity of 66.90% and a net margin of 18.87%.The firm’s revenue for the quarter was up 5.7% on a year-over-year basis. During the same period in the previous year, the company posted $1.46 earnings per share. Bristol Myers Squibb has set its FY 2026 guidance at 6.750-7.000 EPS. On average, sell-side analysts predict that Bristol Myers Squibb Company will post 6.95 EPS for the current year.
Bristol Myers Squibb Dividend Announcement The company also recently announced a quarterly dividend, which was paid on Monday, August 3rd. Stockholders of record on Thursday, July 2nd were paid a $0.63 dividend. The ex-dividend date was Thursday, July 2nd. This represents a $2.52 annualized dividend and a dividend yield of 3.8%. Bristol Myers Squibb’s dividend payout ratio (DPR) is currently 55.51%.
Bristol Myers Squibb News Roundup Here are the key news stories impacting Bristol Myers Squibb this week:
Positive Sentiment: The FDA approved Zenbexus (iberdomide), BMY’s first-in-class CELMoD therapy, for adults with relapsed or refractory multiple myeloma in combination with Darzalex and dexamethasone. The approval adds a potential oncology growth driver and expands BMY’s treatment portfolio in a major cancer market. New FDA Approval Gives Bristol-Myers Squibb Another Potential Oncology Growth Catalyst Positive Sentiment: Zenbexus received accelerated approval based on improved minimal residual disease-negative complete response rates. As the first approved CELMoD therapy in this setting, it could strengthen BMY’s competitive position in multiple myeloma, although continued approval depends on confirmatory evidence. Zenbexus First-in-Class CELMoD Approval Positive Sentiment: BMY is extending clinical development of deucravacitinib, signaling longer-term ambitions in autoimmune diseases and potentially broadening its growth pipeline beyond oncology. Bristol Myers Squibb Extends Deucravacitinib Program Neutral Sentiment: Camzyos continues to gain momentum, but its ability to offset patent pressures on older products depends partly on an upcoming FDA decision regarding adolescent use and competition from rival heart drugs. Can Camzyos Growth Offset Bristol Myers Patent Pressures? Negative Sentiment: BMY ended its Cellares partnership after concluding that the Cell Shuttle platform could not support commercial-scale manufacturing of Breyanzi. The decision raises questions about manufacturing capacity and the pace of Breyanzi growth, despite avoiding further spending under the agreement valued at up to $380 million. Bristol-Myers Squibb’s Cellares Exit Raises Questions Over Breyanzi Growth Negative Sentiment: Senior Vice President Phil Holzer sold 500 BMY shares for approximately $33,750, reducing his holdings by 2.88%. The small transaction is generally a limited signal, but may add modest caution after the stock’s recent advance. Bristol Myers Squibb SVP Sells 500 Shares Negative Sentiment: A patent dispute involving Cytokinetics creates additional legal uncertainty around BMY’s products and could increase future litigation or commercial risks. What Does Bristol Myers Squibb Face After Zenbexus Approval and Patent Action? Wall Street Analyst Weigh In Several research analysts have recently weighed in on BMY shares. UBS Group lowered shares of Bristol Myers Squibb from a “buy” rating to a “neutral” rating in a research note on Wednesday, August 5th. Jefferies Financial Group downgraded Bristol Myers Squibb from a “buy” rating to a “hold” rating in a report on Wednesday, August 5th. Royal Bank Of Canada boosted their price target on Bristol Myers Squibb from $60.00 to $64.00 and gave the company a “sector perform” rating in a research note on Friday, July 31st. Wall Street Zen upgraded shares of Bristol Myers Squibb from a “buy” rating to a “strong-buy” rating in a research note on Saturday, June 27th. Finally, TD Cowen began coverage on Bristol Myers Squibb in a research note on Wednesday, August 5th. They issued a “buy” rating on the stock. One equities research analyst has rated the stock with a Strong Buy rating, thirteen have given a Buy rating, ten have issued a Hold rating and one has given a Sell rating to the stock. Based on data from MarketBeat, Bristol Myers Squibb has an average rating of “Moderate Buy” and a consensus target price of $66.06.
View Our Latest Analysis on BMY
(Free Report)
Bristol Myers Squibb is a global biopharmaceutical company headquartered in Princeton, New Jersey, focused on discovering, developing and delivering medicines for serious diseases. The company’s core activities include research and development, clinical development, manufacturing and commercialization of prescription pharmaceuticals across multiple therapeutic areas. BMS concentrates on advancing therapies in oncology, hematology, immunology, cardiovascular disease and specialty areas through both small molecules and biologics.
BMS’s marketed portfolio and late‑stage pipeline reflect a strong emphasis on cancer and immune‑mediated conditions.
Read More Five stocks we like better than Bristol Myers Squibb Nutanix’s Rally Has a Bigger Story Than Earnings as AMD’s AI Bet Takes Shape SEC Probe Puts Wall Street Leverage Risk Back in Focus A Bearish-Dollar Options Surge Raises the Stakes for Warsh at Jackson Hole Five Below’s Turnaround Is Working—But Has the Stock Run Too Far?
Receive News & Ratings for Bristol Myers Squibb Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Bristol Myers Squibb and related companies with MarketBeat.com's FREE daily email newsletter.
Barbara Oil Co. ve 2. čtvrtletí koupila 42 000 akcií Bristol Myers Squibb za zhruba 2,42 milionu USD. Bristol Myers Squibb zároveň oznámila kvartální EPS 2,04 USD a tržby 12,97 miliardy USD, obojí nad odhady.
Barbara Oil Co. bought a new stake in Bristol Myers Squibb Company (NYSE:BMY – Free Report) in the second quarter, according to its most recent 13F filing with the Securities & Exchange Commission. The fund bought 42,000 shares of the biopharmaceutical company’s stock, valued at approximately $2,420,000.
Several other institutional investors and hedge funds have also recently bought and sold shares of the stock. Davis Asset Management L.P. acquired a new position in shares of Bristol Myers Squibb in the 2nd quarter valued at about $27,000. Swiss RE Ltd. acquired a new stake in Bristol Myers Squibb during the 4th quarter worth approximately $25,000. Physician Wealth Advisors Inc. raised its holdings in Bristol Myers Squibb by 73.5% in the fourth quarter. Physician Wealth Advisors Inc. now owns 477 shares of the biopharmaceutical company’s stock valued at $26,000 after buying an additional 202 shares during the period. Darwin Wealth Management LLC purchased a new position in Bristol Myers Squibb in the second quarter valued at approximately $25,000. Finally, Addison Advisors LLC acquired a new position in Bristol Myers Squibb during the second quarter valued at approximately $32,000. Institutional investors and hedge funds own 76.41% of the company’s stock.
Bristol Myers Squibb Stock Up 0.1% Shares of NYSE BMY opened at $67.06 on Monday. Bristol Myers Squibb Company has a 1 year low of $42.52 and a 1 year high of $68.64. The firm has a market cap of $136.98 billion, a price-to-earnings ratio of 14.77, a PEG ratio of 0.17 and a beta of 0.22. The company has a debt-to-equity ratio of 1.89, a quick ratio of 1.38 and a current ratio of 1.53. The stock’s 50-day simple moving average is $60.55 and its 200-day simple moving average is $59.39.
Bristol Myers Squibb (NYSE:BMY – Get Free Report) last issued its quarterly earnings results on Thursday, July 30th. The biopharmaceutical company reported $2.04 EPS for the quarter, beating analysts’ consensus estimates of $1.60 by $0.44. Bristol Myers Squibb had a return on equity of 66.90% and a net margin of 18.87%.The firm had revenue of $12.97 billion during the quarter, compared to the consensus estimate of $11.74 billion. During the same quarter in the prior year, the business posted $1.46 earnings per share. Bristol Myers Squibb’s revenue for the quarter was up 5.7% on a year-over-year basis. Bristol Myers Squibb has set its FY 2026 guidance at 6.750-7.000 EPS. As a group, equities analysts anticipate that Bristol Myers Squibb Company will post 6.95 earnings per share for the current fiscal year. Bristol Myers Squibb Announces Dividend The company also recently disclosed a quarterly dividend, which was paid on Monday, August 3rd. Shareholders of record on Thursday, July 2nd were paid a dividend of $0.63 per share. The ex-dividend date was Thursday, July 2nd. This represents a $2.52 annualized dividend and a yield of 3.8%. Bristol Myers Squibb’s dividend payout ratio is presently 55.51%.
Wall Street Analysts Forecast Growth Several equities research analysts have recently issued reports on the stock. Truist Financial reissued a “buy” rating and issued a $70.00 price objective (up from $65.00) on shares of Bristol Myers Squibb in a research report on Friday, July 31st. Guggenheim reaffirmed a “buy” rating and set a $75.00 price target (up from $72.00) on shares of Bristol Myers Squibb in a research report on Friday, July 31st. UBS Group downgraded Bristol Myers Squibb from a “buy” rating to a “neutral” rating in a report on Wednesday, August 5th. BMO Capital Markets reissued a “market perform” rating on shares of Bristol Myers Squibb in a research report on Monday, July 27th. Finally, Raymond James Financial initiated coverage on Bristol Myers Squibb in a research note on Wednesday, August 5th. They set a “strong-buy” rating on the stock. One analyst has rated the stock with a Strong Buy rating, thirteen have assigned a Buy rating, ten have issued a Hold rating and one has assigned a Sell rating to the company. According to MarketBeat.com, Bristol Myers Squibb has an average rating of “Moderate Buy” and an average target price of $66.06.
Read Our Latest Research Report on BMY
Key Stories Impacting Bristol Myers Squibb Here are the key news stories impacting Bristol Myers Squibb this week:
Positive Sentiment: Bristol Myers Squibb plans to invest approximately $2.3 billion in a new Houston manufacturing facility, part of a broader $40 billion U.S. investment commitment. The project reinforces BMY’s confidence in domestic production capacity and could support long-term operational growth. Bristol-Myers Squibb Bets $2.3 Billion on Texas Positive Sentiment: BMY is collaborating with Chai Discovery on artificial-intelligence-driven antibody discovery. The partnership could help identify novel therapeutic candidates more efficiently and strengthens the company’s efforts to modernize its drug-development platform. Chai Discovery Collaboration Positive Sentiment: The company is launching a Phase 1 study of an early Alzheimer’s disease antibody. Although the program remains highly experimental, it adds another potential long-term growth opportunity to BMY’s pipeline. Early Alzheimer’s Antibody Study Positive Sentiment: Strong Eliquis performance is helping offset declines in BMY’s older products facing generic pressure, supporting a more favorable 2026 revenue outlook. Elevated call-option activity also signals increased bullish interest, though it is not a fundamental guarantee. Eliquis and Legacy Portfolio Analysis Neutral Sentiment: Early clinical work on navlimetostat shows continued pipeline activity, but the Phase 1-stage program has not yet produced efficacy data that would materially change near-term earnings expectations. Navlimetostat Study Update Negative Sentiment: Generic competition remains a key risk for BMY’s legacy portfolio. Investors must determine whether Eliquis growth and newer pipeline assets can replace revenue lost as established medicines face erosion. Legacy Portfolio Erosion Analysis Bristol Myers Squibb Profile (Free Report)
Bristol Myers Squibb is a global biopharmaceutical company headquartered in Princeton, New Jersey, focused on discovering, developing and delivering medicines for serious diseases. The company’s core activities include research and development, clinical development, manufacturing and commercialization of prescription pharmaceuticals across multiple therapeutic areas. BMS concentrates on advancing therapies in oncology, hematology, immunology, cardiovascular disease and specialty areas through both small molecules and biologics.
BMS’s marketed portfolio and late‑stage pipeline reflect a strong emphasis on cancer and immune‑mediated conditions.
Further Reading Five stocks we like better than Bristol Myers Squibb VIG, VYM, and VYMI: Which Vanguard Dividend ETF Is Right for You? 3 Closed-End Funds to Maximize Dividend Payments Rocket Lab’s Sell-Off Is Fading—Is It Finally Safe to Buy? $27 Billion in Buybacks: 3 Stocks Betting Their Strong Runs Aren’t Over
Receive News & Ratings for Bristol Myers Squibb Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Bristol Myers Squibb and related companies with MarketBeat.com's FREE daily email newsletter.
Blue Capital Inc. ve 2. čtvrtletí nově nakoupila 18 381 akcií Bristol Myers Squibb za zhruba 1,059 milionu USD. Akcie BMY v pátek otevřely o 2,4 % výše.
Blue Capital Inc. acquired a new position in shares of Bristol Myers Squibb Company (NYSE:BMY – Free Report) in the second quarter, according to its most recent filing with the Securities & Exchange Commission. The firm acquired 18,381 shares of the biopharmaceutical company’s stock, valued at approximately $1,059,000.
A number of other hedge funds and other institutional investors have also bought and sold shares of the company. Vanguard Group Inc. increased its position in shares of Bristol Myers Squibb by 1.4% in the fourth quarter. Vanguard Group Inc. now owns 198,727,768 shares of the biopharmaceutical company’s stock valued at $10,719,376,000 after acquiring an additional 2,743,759 shares during the last quarter. BlackRock Inc. boosted its position in Bristol Myers Squibb by 5.1% during the second quarter. BlackRock Inc. now owns 180,384,994 shares of the biopharmaceutical company’s stock valued at $10,393,783,000 after purchasing an additional 8,702,106 shares during the last quarter. State Street Corp grew its stake in Bristol Myers Squibb by 1.4% in the fourth quarter. State Street Corp now owns 97,980,438 shares of the biopharmaceutical company’s stock valued at $5,285,065,000 after purchasing an additional 1,385,206 shares in the last quarter. Geode Capital Management LLC increased its position in shares of Bristol Myers Squibb by 13.1% during the 4th quarter. Geode Capital Management LLC now owns 52,638,346 shares of the biopharmaceutical company’s stock worth $2,837,026,000 after purchasing an additional 6,084,046 shares during the last quarter. Finally, Norges Bank bought a new stake in shares of Bristol Myers Squibb during the 4th quarter worth approximately $1,947,272,000. Institutional investors and hedge funds own 76.41% of the company’s stock.
More Bristol Myers Squibb News Here are the key news stories impacting Bristol Myers Squibb this week:
Positive Sentiment: Bristol Myers Squibb plans to invest approximately $2.3 billion in a new Houston manufacturing facility, part of a broader $40 billion U.S. investment commitment. The project reinforces BMY’s confidence in domestic production capacity and could support long-term operational growth. Bristol-Myers Squibb Bets $2.3 Billion on Texas Positive Sentiment: BMY is collaborating with Chai Discovery on artificial-intelligence-driven antibody discovery. The partnership could help identify novel therapeutic candidates more efficiently and strengthens the company’s efforts to modernize its drug-development platform. Chai Discovery Collaboration Positive Sentiment: The company is launching a Phase 1 study of an early Alzheimer’s disease antibody. Although the program remains highly experimental, it adds another potential long-term growth opportunity to BMY’s pipeline. Early Alzheimer’s Antibody Study Positive Sentiment: Strong Eliquis performance is helping offset declines in BMY’s older products facing generic pressure, supporting a more favorable 2026 revenue outlook. Elevated call-option activity also signals increased bullish interest, though it is not a fundamental guarantee. Eliquis and Legacy Portfolio Analysis Neutral Sentiment: Early clinical work on navlimetostat shows continued pipeline activity, but the Phase 1-stage program has not yet produced efficacy data that would materially change near-term earnings expectations. Navlimetostat Study Update Negative Sentiment: Generic competition remains a key risk for BMY’s legacy portfolio. Investors must determine whether Eliquis growth and newer pipeline assets can replace revenue lost as established medicines face erosion. Legacy Portfolio Erosion Analysis Bristol Myers Squibb Trading Up 2.4% BMY opened at $67.06 on Friday. The company has a market cap of $136.98 billion, a P/E ratio of 14.77, a PEG ratio of 0.17 and a beta of 0.22. The company has a current ratio of 1.53, a quick ratio of 1.38 and a debt-to-equity ratio of 1.89. The company’s 50 day moving average is $60.55 and its 200-day moving average is $59.37. Bristol Myers Squibb Company has a 1-year low of $42.52 and a 1-year high of $68.64. Bristol Myers Squibb (NYSE:BMY – Get Free Report) last issued its earnings results on Thursday, July 30th. The biopharmaceutical company reported $2.04 earnings per share for the quarter, beating analysts’ consensus estimates of $1.60 by $0.44. Bristol Myers Squibb had a net margin of 18.87% and a return on equity of 66.90%. The firm had revenue of $12.97 billion for the quarter, compared to analyst estimates of $11.74 billion. During the same quarter last year, the business posted $1.46 earnings per share. The company’s quarterly revenue was up 5.7% on a year-over-year basis. Bristol Myers Squibb has set its FY 2026 guidance at 6.750-7.000 EPS. Equities research analysts predict that Bristol Myers Squibb Company will post 6.95 earnings per share for the current fiscal year.
Bristol Myers Squibb Announces Dividend The company also recently declared a quarterly dividend, which was paid on Monday, August 3rd. Stockholders of record on Thursday, July 2nd were paid a dividend of $0.63 per share. This represents a $2.52 dividend on an annualized basis and a dividend yield of 3.8%. The ex-dividend date of this dividend was Thursday, July 2nd. Bristol Myers Squibb’s dividend payout ratio (DPR) is presently 55.51%.
Analysts Set New Price Targets Several equities analysts recently weighed in on BMY shares. Truist Financial reissued a “buy” rating and issued a $70.00 target price (up from $65.00) on shares of Bristol Myers Squibb in a research note on Friday, July 31st. Royal Bank Of Canada upped their price target on shares of Bristol Myers Squibb from $60.00 to $64.00 and gave the stock a “sector perform” rating in a research report on Friday, July 31st. Jefferies Financial Group downgraded shares of Bristol Myers Squibb from a “buy” rating to a “hold” rating in a research report on Wednesday, August 5th. Sanford C. Bernstein raised shares of Bristol Myers Squibb from a “market perform” rating to an “outperform” rating in a report on Wednesday, August 5th. Finally, Wall Street Zen upgraded shares of Bristol Myers Squibb from a “buy” rating to a “strong-buy” rating in a research note on Saturday, June 27th. One analyst has rated the stock with a Strong Buy rating, thirteen have assigned a Buy rating, ten have assigned a Hold rating and one has given a Sell rating to the stock. According to data from MarketBeat.com, Bristol Myers Squibb has a consensus rating of “Moderate Buy” and a consensus price target of $66.06.
View Our Latest Stock Analysis on BMY
(Free Report)
Bristol Myers Squibb is a global biopharmaceutical company headquartered in Princeton, New Jersey, focused on discovering, developing and delivering medicines for serious diseases. The company’s core activities include research and development, clinical development, manufacturing and commercialization of prescription pharmaceuticals across multiple therapeutic areas. BMS concentrates on advancing therapies in oncology, hematology, immunology, cardiovascular disease and specialty areas through both small molecules and biologics.
BMS’s marketed portfolio and late‑stage pipeline reflect a strong emphasis on cancer and immune‑mediated conditions.
Featured Articles Five stocks we like better than Bristol Myers Squibb Blueprint for a Boom: SEC Clears the Crypto Runway Ross Stores Just Flipped the Off-Price Retail Story After TJX’s Marmaxx Miss Advance Auto Parts Plunged, But Its Turnaround Is Still Working Is Palo Alto Networks Priced for Perfection Again as AI Security Demand Accelerates?
Receive News & Ratings for Bristol Myers Squibb Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Bristol Myers Squibb and related companies with MarketBeat.com's FREE daily email newsletter.
Advisors Capital Management LLC purchased a new stake in shares of Bristol Myers Squibb Company (NYSE:BMY – Free Report) during the second quarter, according to its most recent filing with the Securities & Exchange Commission. The firm purchased 1,029,843 shares of the biopharmaceutical company’s stock, valued at approximately $59,340,000. Advisors Capital Management LLC owned about 0.05% of Bristol Myers Squibb at the end of the most recent reporting period.
Several other large investors have also recently made changes to their positions in the business. MJP Associates Inc. ADV purchased a new position in Bristol Myers Squibb in the 2nd quarter worth $322,000. PCM Encore LLC purchased a new stake in Bristol Myers Squibb during the second quarter valued at about $313,000. Vise Technologies Inc. purchased a new stake in Bristol Myers Squibb during the second quarter valued at about $8,177,000. OVERSEA CHINESE BANKING Corp Ltd bought a new position in shares of Bristol Myers Squibb during the second quarter valued at about $1,559,000. Finally, E Fund Management Co. Ltd. purchased a new position in shares of Bristol Myers Squibb in the second quarter worth about $742,000. 76.41% of the stock is owned by hedge funds and other institutional investors.
Analyst Upgrades and Downgrades A number of equities research analysts have recently weighed in on the company. Raymond James Financial started coverage on Bristol Myers Squibb in a research note on Wednesday, August 5th. They issued a “strong-buy” rating for the company. Jefferies Financial Group cut Bristol Myers Squibb from a “buy” rating to a “hold” rating in a research note on Wednesday, August 5th. Guggenheim reiterated a “buy” rating and issued a $75.00 price objective (up from $72.00) on shares of Bristol Myers Squibb in a research report on Friday, July 31st. Argus raised Bristol Myers Squibb from a “hold” rating to a “buy” rating and set a $75.00 price objective for the company in a research note on Wednesday, August 5th. Finally, Citigroup restated a “neutral” rating and issued a $70.00 target price (up from $66.00) on shares of Bristol Myers Squibb in a report on Monday, August 3rd. One equities research analyst has rated the stock with a Strong Buy rating, thirteen have given a Buy rating, ten have assigned a Hold rating and one has given a Sell rating to the company’s stock. According to data from MarketBeat.com, the stock has a consensus rating of “Moderate Buy” and an average target price of $66.06.
Get Our Latest Research Report on Bristol Myers Squibb Key Stories Impacting Bristol Myers Squibb Here are the key news stories impacting Bristol Myers Squibb this week:
Positive Sentiment: Bristol Myers Squibb announced a collaboration with Chai Discovery to use artificial intelligence for antibody discovery. The partnership could improve the speed and efficiency of developing new therapies, although financial terms and the near-term earnings impact were not disclosed. Chai Discovery collaboration with Bristol Myers Squibb Positive Sentiment: An update on the Phase 1 study of navlimetostat indicates continued progress in Bristol Myers Squibb’s early-stage pipeline. The program remains experimental, so any commercial benefit is still distant and uncertain. Bristol Myers Squibb navlimetostat study update Positive Sentiment: Hematogenix said its minimal residual disease assay supported the FDA’s accelerated approval of Bristol Myers Squibb’s ZENBEXUS™, described as the first approved CELMoD therapy for multiple myeloma. The approval could expand the company’s oncology opportunity, though accelerated approvals typically require confirmatory evidence. Hematogenix assay and ZENBEXUS approval Positive Sentiment: Unusually heavy call-option activity, with 55,757 calls purchased—more than double the average volume—signals increased speculative interest in BMY. Options activity is not confirmation of a sustained rally and can increase volatility. Positive Sentiment: Analyst coverage continues to characterize BMY as an attractive value stock, supported by its relatively low valuation and income potential. A separate comparison also frames Bristol Myers Squibb as a potential bargain versus AstraZeneca, though these are opinion-based assessments. Zacks BMY value-stock analysis Neutral Sentiment: Articles discussing a covered-call strategy emphasize income generation rather than a bullish outlook for capital appreciation. The strategy may appeal to yield-focused investors but can limit upside if the shares rise sharply. Bristol Myers Squibb options income strategy Neutral Sentiment: A report on Aktis Oncology, which has attracted interest from Bristol Myers Squibb and other large pharmaceutical companies, highlights potential future deal activity but does not announce a transaction or create an immediate financial impact for BMY. Pharmaceutical interest in Aktis Oncology Bristol Myers Squibb Trading Down 3.1% BMY opened at $65.54 on Friday. Bristol Myers Squibb Company has a one year low of $42.52 and a one year high of $68.64. The company has a debt-to-equity ratio of 1.89, a current ratio of 1.53 and a quick ratio of 1.38. The business has a 50 day simple moving average of $60.35 and a two-hundred day simple moving average of $59.31. The firm has a market capitalization of $133.88 billion, a price-to-earnings ratio of 14.44, a PEG ratio of 0.18 and a beta of 0.22.
Bristol Myers Squibb (NYSE:BMY – Get Free Report) last issued its quarterly earnings data on Thursday, July 30th. The biopharmaceutical company reported $2.04 earnings per share for the quarter, topping analysts’ consensus estimates of $1.60 by $0.44. The firm had revenue of $12.97 billion for the quarter, compared to analyst estimates of $11.74 billion. Bristol Myers Squibb had a return on equity of 66.90% and a net margin of 18.87%.The business’s quarterly revenue was up 5.7% compared to the same quarter last year. During the same period last year, the company earned $1.46 EPS. Bristol Myers Squibb has set its FY 2026 guidance at 6.750-7.000 EPS. Analysts predict that Bristol Myers Squibb Company will post 6.95 EPS for the current year.
Bristol Myers Squibb Dividend Announcement The business also recently disclosed a quarterly dividend, which was paid on Monday, August 3rd. Shareholders of record on Thursday, July 2nd were issued a $0.63 dividend. The ex-dividend date was Thursday, July 2nd. This represents a $2.52 annualized dividend and a yield of 3.8%. Bristol Myers Squibb’s dividend payout ratio (DPR) is 55.51%.
Bristol Myers Squibb Profile (Free Report)
Bristol Myers Squibb is a global biopharmaceutical company headquartered in Princeton, New Jersey, focused on discovering, developing and delivering medicines for serious diseases. The company’s core activities include research and development, clinical development, manufacturing and commercialization of prescription pharmaceuticals across multiple therapeutic areas. BMS concentrates on advancing therapies in oncology, hematology, immunology, cardiovascular disease and specialty areas through both small molecules and biologics.
BMS’s marketed portfolio and late‑stage pipeline reflect a strong emphasis on cancer and immune‑mediated conditions.
See Also Five stocks we like better than Bristol Myers Squibb 3 Energy Stocks Raising Dividends as the Sector Surges 5 Reasons the S&P 500 Could Keep Rallying Through Year-End Walmart’s Post-Earnings Drop Could Be a Buying Opportunity The Trade Desk’s Earnings Miss Raises a Bigger Question About Its AI Future Want to see what other hedge funds are holding BMY? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Bristol Myers Squibb Company (NYSE:BMY – Free Report).
Receive News & Ratings for Bristol Myers Squibb Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Bristol Myers Squibb and related companies with MarketBeat.com's FREE daily email newsletter.
Aktis Oncology má v hotovosti 517,3 mil. USD a vedení počítá s financováním do roku 2029. Firma je bez tržeb a její klíčová aktiva mohou být lákadlem pro Novartis, Lilly i Bristol Myers.
This post may contain links from our sponsors and affiliates, and Flywheel Publishing may receive compensation for actions taken through them.
Aktis Oncology (NASDAQ:AKTS) closed at $25.00 on August 18, 2026, giving the clinical-stage radiopharmaceutical company a market cap of $1.4 billion. The stock has traded between $14.72 and $34.19 since its January 2026 initial public offering. Aktis holds $517.3 million in cash, with management guiding runway into 2029. It is pre-revenue except for a single collaboration agreement.
Why a Strategic Buyer Would Want It Aktis operates an isotope-agnostic miniprotein radioconjugate platform designed to deliver 225Ac, a highly potent alpha-emitting radioisotope. Lead candidate [225Ac]Ac-AKY-1189 targets Nectin-4, the same target as Padcev, with an IND cleared in May 2025 and preliminary Part-1 dose escalation data expected in the first quarter of 2027. Second program [225Ac]Ac-AKY-2519 targets B7-H3, expressed in approximately 90% of mCRPC, 80% of NSCLC, and 70% of small cell lung cancers.
What an Acquirer Would Actually Be Buying The rights structure is the differentiator. Aktis retains exclusive, worldwide development and commercialization rights to all current product candidates and discovery programs. The Lilly collaboration covers only targets beyond the scope of the unpartnered pipeline. There are no territorial carve-outs on core assets.
The Lilly Collaboration Agreement includes an upfront license fee of $60.0 million, up to $525.0 million in research, development, regulatory and commercial launch milestones, and up to $630.0 million in sales milestones. The filing inconsistently describes the royalty as “tiered royalties of up to 10%” in one section and “a tiered royalty of up to low-double digits” in another, creating ambiguity about the actual rate. Aktis runs research through initial human imaging studies; Lilly then owns regulatory, clinical development and commercialization. Lilly may terminate on a target-by-target or region-by-region basis upon 60 days’ prior written notice. Its license is limited to products that contain a radioactive isotope. Lilly also indicated interest in purchasing approximately $100.0 million in shares at IPO, making it both partner and shareholder. The S-1 does not spell out change-of-control mechanics, which a third-party bidder would need to diligence.
Ranking the Plausible Acquirers Novartis (NYSE:NVS | NVS Price Prediction) has a $294 billion market cap. It saw its radioligand therapy Pluvicto grow 43% in constant currencies during Q2 2026, as management explicitly stated its intention to progress “beyond Pluvicto and Lutathera, hopefully into additional cancer types.” AKY-2519 in mCRPC is directly adjacent. Eli Lilly (NYSE:LLY) trades at $1,225.73. Ricks said, “We expect to remain active in business development while maintaining discipline.” The existing partnership offers information advantage. Bristol Myers Squibb (NYSE:BMY) has a $132.0 billion market cap. Its Boerner stating BD remains “a top allocation priority.” No comparable radiopharmaceutical franchise exists in the portfolio. What About Private Equity or Alternative Capital? With no product revenue to lever, a traditional leveraged buyout (LBO) does not fit. Realistic non-strategic paths are royalty monetization on the Lilly stream, private investment in public equity (PIPE) structures, or crossover funds ahead of 2027 readouts.
What to Watch Analyst consensus is 100% bullish with a target of $34.42; the 24/7 Wall St. model base case is $42.16 at 0.5 confidence. Catalysts include Q1 2027 AKY-1189 data, 2027 AKY-2519 mCRPC readouts, and the H2 2026 GMP facility. Trial risk is binary; a failed readout removes the takeout premium entirely.
Contact [email protected] for any questions or corrections.
Bristol Myers Squibb získala od FDA zrychlené schválení pro ZENBEXUS v kombinaci s daratumumabem a dexamethasonem k léčbě dospělých pacientů s mnohočetným myelomem, kteří dostali alespoň 1 předchozí linii léčby včetně inhibitoru proteazomu a imunomodulačního agens. Jde o první terapii CELMoD schválenou FDA.
PRINCETON, N.J.--(BUSINESS WIRE)--Bristol Myers Squibb (NYSE: BMY) today announced that the U.S. Food and Drug Administration (FDA) has approved ZENBEXUS™ (iberdomide) in combination with daratumumab and hyaluronidase-fihj and dexamethasone (ZDd) for the treatment of adult patients with multiple myeloma who have received at least one prior line of therapy including a proteasome inhibitor and an immunomodulatory agent.1 Full approval for this indication will be contingent upon verification and description of clinical benefit in the confirmatory trial(s). ZENBEXUS is the first FDA-approved CELMoD, belonging to a new class called cereblon-modulating protein degraders for the treatment of multiple myeloma.1 Please see the Important Safety Information section below, including Boxed WARNINGS for ZENBEXUS regarding embryo-fetal toxicity and venous and arterial thromboembolism. ZENBEXUS is contraindicated in females who are pregnant.1
$BMY announced @US_FDA granted accelerated approval for its first CELMoD in relapsed or refractory #MultipleMyeloma, introducing a new class of treatment.
Share “Today’s approval of ZENBEXUS represents meaningful progress for patients living with multiple myeloma and underscores the power of our targeted protein degradation platform, particularly our CELMoD programs,” said Cristian Massacesi, MD, chief medical officer and head of development at Bristol Myers Squibb. “As the first approved CELMoD, ZENBEXUS marks the arrival of a new treatment class and is an important milestone in our efforts to expand what is possible for patients with multiple myeloma. And we believe this is only the beginning. This approval validates years of scientific research and strengthens our confidence in the potential of this approach as we continue to advance our innovative pipeline on behalf of patients with significant unmet needs.”
Approval of ZENBEXUS is based on results from the Phase 3 EXCALIBER-RRMM trial evaluating ZENBEXUS, daratumumab and hyaluronidase-fihj and dexamethasone (ZDd; n=207) compared to daratumumab, bortezomib and dexamethasone (DVd; n=213) in patients with RRMM.1 At a median follow-up of 16 months, results showed treatment with ZDd demonstrated a statistically significant improvement in one of the dual primary endpoints of minimal residual disease (MRD)-negative complete response (CR) in 41% of patients (n=85; 95% CI: 34-48) vs. 21% of patients (n=44; 95% CI: 15-27) treated with DVd (p < 0.0001).1 MRD-negativity is among the deepest measures of response in multiple myeloma and is considered predictive of improved progression-free survival (PFS).2 This FDA decision marks the first approval in relapsed or refractory multiple myeloma based on MRD-negative CR.
“The FDA approval of iberdomide marks the anticipated arrival of a new therapeutic class for relapsed or refractory multiple myeloma and has the potential to make a meaningful difference for patients,” said Sagar Lonial, MD, FACP, FASCO, EXCALIBER-RRMM lead investigator and chief medical officer of the Winship Cancer Institute of Emory University. “The strong results observed with the CELMoD-based combination within a familiar triplet approach creates the potential for a new treatment foundation in multiple myeloma.”
The combination of ZDd was observed to have a safety profile that is expected of the combination, with 7.8% of patients discontinuing ZDd due to adverse reactions.1 Among the key safety findings, ZDd can cause serious, life-threatening, or fatal infections and severe neutropenia.1 Neutropenia and infections in patients who received ZDd occurred at a rate of 90.2% and 78.9%, respectively, leading to few discontinuations (1% and 1.5%, respectively).1 The most common adverse reactions (≥20%) in the ZDd arm and DVd arm, respectively, were upper respiratory tract infection (54% and 52%), fatigue (36% and 33%), musculoskeletal pain (35% and 33%), pneumonia (34% and 17%), diarrhea (33% and 36%), motor dysfunction (26% and 17%), rash (26% and 15%), sleep disorder (25% and 28%), hypogammaglobulinemia (24% and 12%), COVID-19 (23% and 16%), and constipation (20% and 22%).1 Serious adverse reactions in ≥2% of patients included pneumonia (26%), upper respiratory tract infection (6.4%), second primary malignancy (5.9%), neutropenia (4.9%), febrile neutropenia (3.9%), COVID-19 (4.4%), and sepsis (2.9%).1 Fatal adverse reactions occurred in 10 patients (4.9%) who received ZENBEXUS.1 Sepsis (1.5%) was the only fatal drug reaction that occurred in more than 1 patient.1 The following fatal adverse reactions occurred in 1 patient each: listeria encephalitis, influenza, lung adenocarcinoma, cardiac arrest, large intestine perforation, metabolic acidosis, and respiratory failure.1
“The goal for every person living with multiple myeloma is not simply to live longer, but to live well,” said Heather Cooper Ortner, president and chief executive officer of the International Myeloma Foundation. “That is why it is important to have access to effective therapeutic options, particularly in the community setting where the majority of myeloma care is delivered. This approval represents an important step forward by expanding treatment options for patients facing their first relapse. Every new option gives patients and their healthcare teams additional choices as treatment needs evolve, as well as renewed hope for the future.”
ZENBEXUS was granted Breakthrough Therapy designation and accelerated approval based on MRD-negative CR at any time in the EXCALIBER-RRMM study.1 This review was conducted under the FDA’s Project Orbis initiative, which enables concurrent review by the health authorities in several other countries.
While ZENBEXUS is the first FDA approved CELMoD therapy, a New Drug Application for mezigdomide, an investigational CELMoD, in combination with carfilzomib and dexamethasone is also currently under review with the FDA with a Prescription Drug User Fee Act target date of May 13, 2027.
Bristol Myers Squibb offers various programs and resources to address the needs of patients and caregivers, and provides support that allows for access to therapies, including ZENBEXUS.
About EXCALIBER-RRMM
EXCALIBER-RRMM (NCT04975997) is a Phase 3, multicenter, two-stage, randomized, open-label study evaluating the efficacy and safety of ZENBEXUS (iberdomide) in combination with daratumumab and hyaluronidase-fihj and dexamethasone (ZDd) versus daratumumab, bortezomib, and dexamethasone (DVd) in patients with relapsed or refractory multiple myeloma (RRMM).2 The study included a dose optimization stage and was designed to assess dual-primary endpoints of minimal residual disease (MRD) negativity and progression-free survival (PFS), with additional secondary endpoints including overall survival (OS), overall response rate (ORR), safety and sustained MRD negativity.2 The study remains ongoing to assess the primary endpoint of PFS. Eligible participants included adults with 1 to 2 prior lines of anti-myeloma therapy and progressive disease.2 A total of 939 patients were randomized.1 The primary efficacy population for MRD negativity included the first 420 patients randomized to the ZENBEXUS (1 mg) + Dd arm (n=207) or the comparator daratumumab, bortezomib, and dexamethasone (DVd) arm (n=213).1 Treatment in both arms was administered until disease progression or unacceptable toxicity.1
This approval, the first in RRMM based on MRD-negative complete response (CR), marks the first public disclosure of MRD-negative CR data from the EXCALIBER-RRMM trial. The MRD data were first disclosed at the time of approval to preserve the integrity of the study while additional endpoints mature. The study remains ongoing, with patients continuing to be evaluated for PFS, one of the trial's dual primary endpoints. Full data from EXCALIBER-RRMM are expected this year.
About Minimal Residual Disease (MRD)
Minimal residual disease (MRD) refers to the small number of cancer cells that may remain in a patient’s body after treatment and are undetectable using conventional diagnostic methods.3 In multiple myeloma, MRD assessment has emerged as a highly sensitive and clinically meaningful tool for evaluating treatment response.3 MRD negativity does not necessarily mean all cancer cells are gone.3
Modern MRD detection methods, such as next-generation sequencing (NGS) and next-generation flow cytometry (NGF), can identify one malignant cell among 100,000 (threshold for MRD) to 1,000,000 normal cells, offering unprecedented precision in measuring disease burden.3 MRD is increasingly being used in clinical trials as a surrogate endpoint for progression-free survival (PFS) and is gaining recognition from regulatory authorities for its role in accelerating approval timelines.2
Indication
ZENBEXUS (iberdomide) in combination with daratumumab and hyaluronidase-fihj and dexamethasone is indicated for the treatment of adult patients with multiple myeloma who have received at least 1 prior line of therapy including a proteasome inhibitor and an immunomodulatory agent.
This indication is approved under accelerated approval based on minimal residual disease (MRD)-negative complete response (CR) at any time. Continued approval for this indication may be contingent upon verification and description of clinical benefit in a confirmatory trial(s).
IMPORTANT SAFETY INFORMATION
CONTRAINDICATIONS
Based on the mechanism of action and findings in animal studies, ZENBEXUS can cause birth defects or embryo-fetal death in humans. ZENBEXUS is contraindicated in females who are pregnant. If this drug is used during pregnancy or if the patient becomes pregnant while taking this drug, the patient should be informed of the potential hazard to a fetus.
WARNINGS AND PRECAUTIONS
Embryo-Fetal Toxicity
Females of Reproductive Potential: Must avoid pregnancy while taking ZENBEXUS and for at least 4 weeks after completing therapy. Advise females of reproductive potential of the potential risk to a fetus and to use 2 methods of effective contraception for at least 4 weeks before beginning ZENBEXUS therapy, during therapy, during dose interruptions and for at least 4 weeks after the last dose of ZENBEXUS therapy. Refer patients who can become pregnant to a qualified provider of contraceptive methods, if needed.
Two negative pregnancy tests with a sensitivity of at least 25 mIU/mL must be obtained prior to initiating therapy. Pregnancy testing should be performed weekly during the first 4 weeks of treatment. Thereafter, testing should occur every 4 weeks in patients with regular menstrual cycles, or every 2 weeks in patients with irregular menstrual cycles.
Females of reproductive potential taking ZENBEXUS must not donate eggs during treatment and for 4 weeks after completion.
Males: ZENBEXUS may pass into human semen. Advise patients who can impregnate partners to use effective contraception during treatment and for 4 weeks following the discontinuation of ZENBEXUS therapy. Male patients taking ZENBEXUS must not donate sperm during treatment and for 4 weeks after completion.
Blood Donation: Patients must not donate blood during treatment with ZENBEXUS and for 4 weeks following discontinuation of ZENBEXUS therapy.
ZENBEXUS REMS
ZENBEXUS is available only through a restricted program called ZENBEXUS REMS, because of the risk of embryo-fetal toxicity. Prescribers must be certified with and patients must be enrolled in the ZENBEXUS REMS Program and comply with ongoing monitoring and contraception requirements. Further information about ZENBEXUS REMS, including information for pharmacies, wholesalers, and distributors, is available at www.ZENBEXUSREMS.com or by telephone at 1-888-423-5436.
Serious Venous and Arterial Thromboembolism
ZENBEXUS can cause serious and life-threatening venous thromboembolic events (DVT and PE) and arterial thromboembolic events (myocardial infarction and stroke). In the EXCALIBER-RRMM study (N=204), venous thromboembolic events occurred in 6.4% of patients treated with ZENBEXUS combined with daratumumab and hyaluronidase-fihj and dexamethasone (IberDd) despite mandatory thromboembolism prophylaxis. The incidence of DVT was 3.4% and the incidence of PE was 1.5%.
Arterial thromboembolic events occurred in 3.4% of patients. The incidence of myocardial infarction was 2.0%, and the incidence of stroke (CVA) was 1.5%.
Monitor patients for signs and symptoms of thromboembolic events during treatment with ZENBEXUS. Patients with known risk factors, including prior thrombosis, may be at greater risk, and actions should be taken to try to minimize all modifiable factors (e.g., hyperlipidemia, hypertension, smoking). Thromboprophylaxis is recommended, and the choice of regimen should be based on assessment of the patient's underlying risk factors. In patients who develop a thromboembolism, interrupt ZENBEXUS and initiate anticoagulant therapy according to guidelines.
Neutropenia
ZENBEXUS can cause severe neutropenia. In the EXCALIBER-RRMM study, all-grade neutropenia was reported in 90.2%, Grade 3 in 30.9%, and Grade 4 in 53.4% of patients in the IberDd arm. Febrile neutropenia occurred in 5.4% of patients.
Monitor complete blood count throughout treatment with ZENBEXUS. Interrupt, reduce dosage, or discontinue ZENBEXUS, as necessary. Initiate granulocyte colony-stimulating factor (GCSF) as appropriate per guidelines.
Infections
ZENBEXUS can cause serious infections, including life-threatening or fatal infections. Patients with active or uncontrolled infection should not start ZENBEXUS treatment until the infection is controlled. In the EXCALIBER-RRMM study, infections, including opportunistic infections, were reported in 78.9%, Grade 3 in 35.8%, Grade 4 in 3.4%, and fatal infections in 2% of patients receiving IberDd. Serious infections occurred in 40% of patients. Discontinuations due to infections occurred in 1.5% of patients.
Monitor patients for signs and symptoms of infection prior to and during treatment with ZENBEXUS and treat appropriately. Withhold or reduce the dose based on severity.
Consider prophylactic anti-infective medications according to current practice guidelines.
Second Primary Malignancies
In the EXCALIBER-RRMM study, at a median follow-up time of 16 months, second primary malignancies (SPM) occurred in 6.9% of patients in the IberDd arm and 4.9% of patients in the daratumumab and hyaluronidase-fihj, bortezomib, and dexamethasone (DVd) arm.
Monitor patients for the development of SPM.
ADVERSE REACTIONS
Serious adverse reactions occurred in 58.3% of patients receiving ZENBEXUS. Serious adverse reactions in ≥2% of patients included pneumonia (26%), upper respiratory tract infection (6.4%), SPM (5.9%), neutropenia (4.9%), febrile neutropenia (3.9%), COVID-19 (4.4%), and sepsis (2.9%). Fatal adverse reactions occurred in 10 patients (4.9%) who received ZENBEXUS. Sepsis (1.5%) was the only fatal drug reaction that occurred in more than 1 patient. The following fatal adverse reactions occurred in 1 patient each: listeria encephalitis, influenza, lung adenocarcinoma, cardiac arrest, large intestine perforation, metabolic acidosis, and respiratory failure.
The most common adverse reactions (≥20%) in the IberDd arm and DVd arm, respectively, were upper respiratory tract infection (54% and 52%), fatigue (36% and 33%), musculoskeletal pain (35% and 33%), pneumonia (34% and 17%), diarrhea (33% and 36%), motor dysfunction (26% and 17%), rash (26% and 15%), sleep disorder (25% and 28%), hypogammaglobulinemia (24% and 12%), COVID-19 (23% and 16%), and constipation (20% and 22%).
The most common Grade 3 to 4 laboratory abnormalities (≥30%) in the IberDd arm and DVd arm, respectively, were neutropenia (77% and 11%), leukopenia (69% and 18%), and lymphopenia (62% and 51%).
DRUG INTERACTIONS
Effects of Other Drugs on ZENBEXUS
Strong or Moderate CYP3A Inhibitors: Coadministration of ZENBEXUS with strong or moderate CYP3A inhibitors should be avoided. If a strong or moderate CYP3A inhibitor must be used in combination with ZENBEXUS, reduce the ZENBEXUS dose. Concomitant use with strong or moderate CYP3A inhibitors may increase the risk of adverse reactions.
Strong or Moderate CYP3A Inducers: Coadministration of ZENBEXUS with strong or moderate CYP3A inducers should be avoided. Concomitant use with a strong or moderate CYP3A inducer may decrease the efficacy of ZENBEXUS.
SPECIFIC POPULATIONS
Pregnancy (See the BOXED WARNINGS)
There is a pregnancy exposure registry that monitors outcomes in patients exposed to ZENBEXUS during pregnancy. See the ZENBEXUS REMS WARNINGS AND PRECAUTIONS section.
Lactation
Advise women not to breastfeed during treatment with ZENBEXUS. Refer to the Prescribing Information for daratumumab hyaluronidase-fihj or dexamethasone for additional information.
Females and Males of Reproductive Potential
ZENBEXUS can cause fetal harm when administered during pregnancy.
Pregnancy Testing, Females of Reproductive Potential, and Males: See the Embryo-Fetal Toxicity WARNINGS AND PRECAUTIONS section.
Geriatric Use
In patients treated with IberDd, the incidence of serious adverse reactions was 53%, 56%, and 74% in adult patients younger than 65 years of age, 65 years of age to younger than 75 years of age, and 75 years of age and older, respectively.
Renal Impairment
Reduce the ZENBEXUS dose in patients with estimated glomerular filtration rate (eGFR) less than 30 mL/min/1.73 m2 not on dialysis. If dose modification is needed due to adverse events, reduce the ZENBEXUS dose to 1 mg every other day on Days 1 to 21 of a 28-day cycle.
Please see full Prescribing Information for ZENBEXUS including Boxed WARNINGS.
About Targeted Protein Degradation and CELMoD
Targeted protein degradation (TPD) is a differentiated research platform at Bristol Myers Squibb built on more than two decades of scientific expertise, providing new avenues to degrade therapeutically relevant proteins that were previously considered difficult to address. BMS is the only company that has successfully developed and commercialized protein degrader agents for the treatment of multiple myeloma. These agents, known as immunomodulatory drugs (IMiDs), helped establish the current standard of care in the treatment of this disease, which remains without a cure. BMS is building on this foundation with several investigational protein degraders in clinical trials, leveraging three different modalities including cereblon E3 ligase modulators (CELMoDs), ligand-directed degraders (LDDs), and degrader antibody conjugates (DACs). This three-pronged approach enables matching the right therapeutic modality to a molecular mechanism of action to modulate targets most effectively and ultimately provides more opportunities for potential breakthroughs that may offer meaningful new options for patients across a broad range of diseases, in and beyond hematology and oncology. Learn more about the science behind TPD at Bristol Myers Squibb here.
About Ongoing Trials
ZENBEXUS™ is also being evaluated in the EXCALIBER Maintenance study.
About Bristol Myers Squibb: Transforming Patients' Lives Through Science
At Bristol Myers Squibb, our mission is to discover, develop and deliver innovative medicines that help patients prevail over serious diseases. We are pursuing bold science to define what's possible for the future of medicine and the patients we serve. For more information about Bristol Myers Squibb, visit us at BMS.com or follow us on LinkedIn, X, YouTube, Facebook and Instagram.
Cautionary Statement Regarding Forward-Looking Statements
This press release contains “forward-looking statements” within the meaning of the Private Securities Litigation Reform Act of 1995 regarding, among other things, the research, development and commercialization of pharmaceutical products. All statements that are not statements of historical facts are, or may be deemed to be, forward-looking statements. Such forward-looking statements are based on current expectations and projections about our future financial results, goals, plans and objectives and involve inherent risks, assumptions and uncertainties, including internal or external factors that could delay, divert or change any of them in the next several years, that are difficult to predict, may be beyond our control and could cause our future financial results, goals, plans and objectives to differ materially from those expressed in, or implied by, the statements. These risks, assumptions, uncertainties and other factors include, among others, whether ZENBEXUS™(iberdomide) in combination with daratumumab and hyaluronidase-fihj and dexamethasone (ZDd) for the indication described in this release will be commercially successful, any marketing approvals, if granted, may have significant limitations on their use, and, that continued approval of ZENBEXUS™ (iberdomide) in combination with daratumumab and hyaluronidase-fihj and dexamethasone (ZDd) described in this release may be contingent upon verification of progression-free survival, the dual primary endpoint of the EXCALIBER-RRMM trial and potential further verification and description of clinical benefit in confirmatory trials. No forward-looking statement can be guaranteed. Forward-looking statements in this press release should be evaluated together with the many risks and uncertainties that affect Bristol Myers Squibb’s business and market, particularly those identified in the cautionary statement and risk factors discussion in Bristol Myers Squibb’s Annual Report on Form 10-K for the year ended December 31, 2025, as updated by our subsequent Quarterly Reports on Form 10-Q, Current Reports on Form 8-K and other filings with the Securities and Exchange Commission. The forward-looking statements included in this document are made only as of the date of this document and except as otherwise required by applicable law, Bristol Myers Squibb undertakes no obligation to publicly update or revise any forward-looking statement, whether as a result of new information, future events, changed circumstances or otherwise.
corporatefinancial-news
References
ZENBEXUS Prescribing Information. ZENBEXUS U.S. Product Information. August 2026. Princeton, N.J.: Bristol Myers Squibb Company. Lonial S, Dimopoulos MA, Berdeja JG, et al. EXCALIBER-RRMM: a phase III trial of iberdomide, daratumumab, and dexamethasone in relapsed/refractory multiple myeloma. Future Oncol. 2025;21(14):1761-1769. doi:10.1080/14796694.2025.2501920 Szalat RE, Anderson KC, Munshi NC. Role of minimal residual disease assessment in multiple myeloma. Haematologica. 2024;109(7):2049-2059. doi:10.3324/haematol.2023.284662.
Atrium Therapeutics získala od Bristol Myers Squibb další milníkovou platbu 15 milionů USD za úspěšné dodání vedoucího kandidáta v rámci spolupráce na kardiologii.
, /PRNewswire/ -- Atrium Therapeutics, Inc. (Nasdaq: RNA) ("Atrium," "Atrium Therapeutics" or the "Company"), a biopharmaceutical company dedicated to delivering RNA therapeutics to the heart, today announced it has earned another $15 million milestone payment from Bristol Myers Squibb (NYSE: BMY) based on the successful delivery of a lead compound targeting an undisclosed cardiology indication under the Company's ongoing collaboration.
"Atrium's vision is to deliver treatments that address the underlying cause of serious heart disease, including rare genetic cardiomyopathies," said Kathleen Gallagher, President and CEO of Atrium Therapeutics. "Advancing a second lead compound under our collaboration with Bristol Myers Squibb reflects the strength and versatility of our RNA delivery platform, and it gives us continued momentum as we work together to bring novel therapies to patients and families facing significant unmet need."
The payment is pursuant to Atrium's global licensing and research collaboration with Bristol Myers Squibb (BMS) focused on the discovery, development and commercialization of innovative RNA-based therapies for multiple cardiovascular indications.
Under the terms of the agreement, Atrium is eligible to receive up to approximately $1.35 billion in research and development milestone payments, up to approximately $825 million in commercial milestone payments, and tiered royalties up to low double-digits on net sales. BMS will fund all future clinical development, regulatory and commercialization activities coming from the collaboration.
About Atrium Therapeutics
Atrium Therapeutics, Inc. (Nasdaq: RNA) is pioneering targeted delivery of ribonucleic acid (RNA) therapeutics to the heart to transform the standard of care for people living with cardiomyopathies. With the U.S. Food and Drug Administration's (FDA) recent clearance of its Investigational New Drug (IND) application for ATR 1072 for PRKAG2 (Protein Kinase AMP-activated non-catalytic subunit Gamma 2) syndrome, Atrium is advancing its first precision cardiology program into the clinic through the Corventis Phase 1/2 clinical trial. The Company's proprietary technology - designed at Avidity Biosciences, Inc. - combines the tissue selectivity of monoclonal antibodies (mAbs) and other targeted delivery ligands with the precision of oligonucleotides, and is designed to selectively target the underlying drivers of genetically driven cardiac diseases through targeted, non-viral delivery of small interfering RNA (siRNA). This approach builds upon learnings from demonstrated delivery to skeletal muscle and applies it for efficient delivery to the heart, with the potential to overcome challenges associated with non-specific tissue delivery. Beyond ATR 1072, the Company's pipeline includes ATR 1086 for PLN (phospholamban) cardiomyopathy and two undisclosed research targets in rare cardiomyopathies.
For more information about our RNA delivery platform, development pipeline and people, please visit https://atriumtherapeutics.com/ and engage with us on LinkedIn.
Availability of Other Information About Atrium Therapeutics
Investors and others should note that Atrium Therapeutics communicates with its investors and the public using its website https://atriumtherapeutics.com/, including, but not limited to, Atrium Therapeutics' disclosures, investor presentations and FAQs, Securities and Exchange Commission (SEC) filings, press releases, public conference call transcripts and webcast transcripts, as well as on LinkedIn. The information that Atrium Therapeutics posts on its website or on LinkedIn could be deemed to be material information. As a result, Atrium Therapeutics encourages investors, the media and others interested to review the information that it posts there on a regular basis. The contents of Atrium Therapeutics' website or social media shall not be deemed incorporated by reference in any filing under the Securities Act of 1933, as amended.
Forward-Looking Statements
This press release contains forward-looking statements within the meaning of the United States Private Securities Litigation Reform Act of 1995, including, without limitation, statements regarding: Atrium's strategy, business plans and objectives; the strength, versatility and potential of Atrium's RNA delivery platform; the advancement, development and potential commercialization of programs under Atrium's collaboration with BMS; the potential for Atrium to receive future milestone payments and royalties under the collaboration with BMS; the ability of the collaboration with BMS to generate additional development candidates and novel therapies; the potential therapeutic benefits of RNA-based therapies; and the potential to address significant unmet medical needs for patients with cardiovascular diseases. Forward-looking statements can generally be identified by words such as "potential," "can," "will," "plan," "may," "could," "would," "expect," "seek," "anticipate," "look forward," "believe," "committed," "continue," "intend," or similar terms. You should not place undue reliance on these statements. Such forward-looking statements are based on our current beliefs and expectations regarding future events, and are subject to significant known and unknown risks and uncertainties. Particular areas where risks or uncertainties could cause Atrium's actual results to be materially different than those expressed in Atrium's forward-looking statements include but are not limited to: the initiation, timing, progress, potential registrational quality, and results of our research and development programs, preclinical studies, any clinical trials, and other regulatory submissions; the beneficial characteristics, including potential safety, efficacy and therapeutic effects of our product candidates and the potential advantages of our product candidates compared to alternative therapies; the success and capabilities of the RNA delivery platform; the prevalence of certain diseases and conditions we intend to treat and our estimates of the potential market opportunity for our product candidates; the timing of and costs involved in obtaining and maintaining regulatory approval of our current and any future product candidates; our ability to develop our current and future product candidates; the implementation of our strategic plans for our business, product candidates, research programs and technologies; developments related to our competitors and our industry; our competitive position and the success of competing therapies that are or may become available; our ability to maintain our current license agreements and collaborations and identify and enter into future license agreements and collaborations; the expected potential benefits of strategic collaborations with third parties and our ability to attract collaborators in the future; our reliance on third parties for manufacturing and to conduct preclinical studies and clinical trials of our product candidates; our ability to efficiently and cost-effectively conduct our current and future clinical trials; our ability to achieve future development, regulatory or commercial milestones under our collaboration with BMS, and to receive associated milestone payments and royalties; the costs of operating as a public company; the accuracy of our estimates regarding future expenses, future revenue, capital requirements and the need for additional financing; the period over which we estimate our existing cash and cash equivalents will be sufficient to fund our future operating expenses and capital expenditure requirements; and other factors specified in Atrium's Quarterly Report on Form 10-Q for the quarter ended March 31, 2026 publicly filed by Atrium with the SEC and in other filings and furnishings made by Atrium with the SEC from time to time. Atrium is providing the information in this communication as of this date and does not undertake any obligation to update any forward-looking statements contained in this communication as a result of new information, future events or otherwise, except as required by law.
Růstové produkty Bristol Myers Squibb vzrostly v první polovině roku 2026 o 13 % a tvořily 56 % tržeb. Starší léky stále dělají 44 % tržeb a dál erodují po ztrátě patentové ochrany.
Key Takeaways Growth products rose 13% in the first half of 2026, reaching 56% of Bristol Myers' total revenuesOpdivo Qvantig, Reblozyl, Breyanzi, Opdualag, Camzyos and Cobenfy propelled first-half growth.Legacy products still make up 44% of revenues and face erosion after multiple patent losses. Bristol Myers Squibb (BMY - Free Report) is navigating a revenue mix shift as growth products portfolio now assumes a larger role in the business, helping mitigate the impact of declining sales from mature products facing generics.
The growth portfolio — including Opdivo, Opdivo Qvantig, Orencia, Yervoy, Reblozyl, Camzyos, Breyanzi, Opdualag, Zeposia, Sotyku, Krazati and Cobenfy — is becoming central to top-line resilience.
Sales from this segment rose 13% in the first half of 2026, lifting its contribution to 56% of total revenues from 51.8% in the first half of 2025. The stronger mix underscores improving revenue durability and supports a more favorable long-term growth outlook.
Within this mix, Reblozyl, Breyanzi, Opdualag, Opdivo Qvantig, Camzyos and Cobenfy propelled growth in the first half.
Opdivo Qvantig (nivolumab and hyaluronidase-nvhy - subcutaneous formulation) has witnessed strong uptake across all approved tumor types in the United States. Opdivo Qvantig is now generating annualized revenues of more than $1 billion.
Other key drugs are contributing to revenue growth, though at varying stages of maturity.
Opdualag continues to benefit from robust global demand and its leading position as a standard of care in first-line melanoma in the United States.
Reblozyl continues to deliver a stellar performance, driven by solid uptake in first-line MDS-associated anemia, sustained strength in the second-line setting and further penetration among first-line RS-negative patients.
Breyanzi’s sales continue to be solid, underscoring its strong commercial momentum. Growth is being driven by its best-in-class profile and robust demand across approved large B-cell lymphoma indications in the United States and international markets. The strong performance highlights sustained demand for the therapy and supports expectations for continued commercial expansion.
Cardiovascular drug Camzyos continues to deliver solid performance, supported by ongoing promotional efforts, an expanding base of new patient prescribers and deeper penetration into the community setting.
In immunology, Sotyktu remains an important growth driver. The recent approval in psoriatic arthritis expands its commercial opportunity and strengthens BMY’s presence in rheumatology. Additional upside could come from ongoing phase III programs in systemic lupus erythematosus and Sjögren’s disease, which may further broaden the drug’s addressable market, if successful.
Newer products such as Cobenfy for schizophrenia provide additional long-term optionality. Early launch momentum and potential label expansions could establish Cobenfy as another meaningful growth driver over time.
However, the portfolio transition remains a key challenge. Legacy products, including Eliquis, Revlimid, Pomalyst, Sprycel and Abraxane, still account for 44% of revenues and continue to face significant erosion following the loss of exclusivity for Revlimid, Pomalyst, Sprycel and Abraxane.
BMY’s Competition in Oncology SpaceOncology is a key therapeutic area of focus for Bristol Myers, which is developing and delivering transformational medicines in this space.
The company competes with big pharma giants like Merck (MRK - Free Report) and Pfizer (PFE - Free Report) in this space.
The immuno-oncology space is dominated by pharma giant MRK’s blockbuster drug Keytruda (pembrolizumab).
Keytruda is approved for several types of cancer and alone accounts for around 48% of MRK’s pharmaceutical sales. Merck is currently working on different strategies to drive long-term growth of Keytruda.
Pfizer is one of the largest and most successful drugmakers in the field of oncology. It has an innovative oncology product portfolio of antibody-drug conjugates (ADCs), small molecules, bispecifics and other immune-oncology biologics that treat a wide range of cancers, including breast cancer, gastrointestinal cancer, genitourinary cancer, hematology-oncology, and thoracic cancers, including lung cancer.
Pfizer’s position in oncology was strengthened with the addition of Seagen.
The company inked a licensing agreement with 3SBio for the development, manufacturing and commercialization of SSGJ-707, a bispecific antibody targeting PD-1 and VEGF, outside China.
BMY’s Price Performance, Valuation & EstimatesShares of Bristol Myers have gained 17.9% year to date compared with the industry’s growth of 6%.
Image Source: Zacks Investment Research
From a valuation standpoint, BMY is trading at a discount to the large-cap pharma industry. Going by the price/earnings ratio, shares currently trade at 9.63X forward earnings, higher than its mean of 8.62X but lower than the large-cap pharma industry’s 18.91X.
Image Source: Zacks Investment Research
The Zacks Consensus Estimate for 2026 EPS has moved north to $6.81 from $6.32 in the past 60 days, while that for 2027 EPS has moved north to $6.42 from $6.05 in the same time frame.
Image Source: Zacks Investment Research
BMY currently carries a Zacks Rank #3 (Hold). You can see the complete list of today’s Zacks #1 Rank (Strong Buy) stocks here.
Mezi společnostmi AstraZeneca a Bristol Myers Squibb neprobíhají žádná jednání o možné dohodě, uvedl zdroj blízký věci. Tím popřel spekulace o velké fúzi v hodnotě téměř 400 miliard USD.
A sign stands outside a Bristol Myers Squibb facility in Cambridge, Massachusetts, U.S., May 20, 2021. REUTERS/Brian Snyder/File Photo Purchase Licensing Rights, opens new tab
CompaniesAug 5 (Reuters) - There are "no discussions" ongoing between AstraZeneca (AZN.L), opens new tab and Bristol Myers Squibb (BMY.N), opens new tab over a potential deal, a senior source close to the matter told Reuters on Wednesday, quashing the prospect of a mooted mega merger between the drugmakers.
"There is no deal between AstraZeneca and BMS. There never was a deal to be done, and there are no discussions between the companies," said the source, speaking on condition of anonymity.
Keep up with the latest medical breakthroughs and healthcare trends with the Reuters Health Rounds newsletter. Sign up here.
AstraZeneca and Bristol Myers Squibb both declined to comment in response to emailed questions from Reuters.
On Sunday Reuters reported, citing a person familiar with the situation, that the two drugmakers had held preliminary talks about a possible deal that would create a pharmaceutical behemoth with a combined value of nearly $400 billion.
Reuters was unable to ascertain at that time if the discussions remained ongoing.
The Financial Times first reported news of the talks.
AstraZeneca shares slid around 9% after the reports of the deal talks, while Bristol Myers shares had held more steady.
Reporting by Maggie Fick and Sabrina Valle; Additional reporting by Amy-Jo Crowley; Editing by Adam Jourdan and Jan Harvey
Our Standards: The Thomson Reuters Trust Principles., opens new tab
Maggie is a Britain-based reporter covering the European pharmaceuticals industry with a global perspective. In 2023, Maggie's coverage of Danish drugmaker Novo Nordisk and its race to increase production of its new weight-loss drug helped the Health & Pharma team win a Reuters Journalists of the Year award in the Beat Coverage of the Year category. Since November 2023, she has also been participating in Reuters coverage related to the Israel-Hamas war. Previously based in Nairobi and Cairo for Reuters and in Lagos for the Financial Times, Maggie got her start in journalism in 2010 as a freelancer for The Associated Press in South Sudan.
NY-based correspondent reporting on some of the largest deals in Healthcare and Industrials. Previously based in Houston, covering global operations of U.S. oil majors. Sabrina has a two-decade career in Business reporting, with a strong background in source-based enterprise and investigations. She previously worked at Bloomberg, Washington Post and has been based in Rio and D.C. covering large corporations, including finance, corruption and geopolitics.
AstraZeneca podle FT jedná s Bristol Myers Squibb o možném spojení, které by vytvořilo jednu z největších farmaceutických skupin světa s hodnotou téměř 400 miliard USD.
Test tubes are seen in front of a displayed Bristol Myers Squibb logo in this illustration taken, May 21, 2021. REUTERS/Dado Ruvic/Illustration/File Photo Purchase Licensing Rights, opens new tab
CompaniesAug 2 (Reuters) - UK drugmaker AstraZeneca (AZN.L), opens new tab has been exploring a deal to combine with U.S. rival Bristol Myers Squibb (BMY.N), opens new tab, the Financial Times reported on Sunday, citing people familiar with the matter.
The deal could create one of the world's biggest pharmaceutical groups with a combined value of nearly $400 billion.
Jumpstart your morning with the latest legal news delivered straight to your inbox from The Daily Docket newsletter. Sign up here.
The companies have held talks on a potential tie-up in recent months, the report said, adding that a deal could materialise soon, but could also be delayed or fall apart.
Reuters could not immediately verify the report. AstraZeneca declined to comment, while Bristol Myers did not immediately respond to a Reuters request for comment outside regular business hours.
Last year, AstraZeneca unveiled plans for a direct U.S. listing, aiming to capitalise on stronger valuations in the U.S. market while remaining listed in London.
The company's share price has more than quadrupled during Pascal Soriot's 14-year tenure as CEO, soaring above the wider FTSE 100 index and main British rival GSK (GSK.L), opens new tab.
Second-quarter results last week showed strong demand for cancer and rare disease drugs continues to drive growth. Cancer treatments accounted for about $25 billion in 2025 sales, nearly half of the total, followed by cardiovascular, renal and metabolism treatments worth about $12 billion.
The report of the potential deal comes about a dozen years after AstraZeneca fended off a takeover attempt by larger U.S. rival Pfizer (PFE.N), opens new tab.
Reporting by Devika Nair in Bengaluru and Mi; Editing by Paul Simao and Bill Berkrot
Our Standards: The Thomson Reuters Trust Principles., opens new tab
Bristol-Myers Squibb ve 2. čtvrtletí zvýšila výnosy na 12,97 miliardy USD a upravený EPS na 2,04 USD. Zároveň zvedla výhled zředěného EPS pro rok 2026 na 6,75–7 USD.
SummaryBristol-Myers Squibb Company ends the second quarter on a high note.On June 28, BMY stock reached a 52-week high of $64.96.In my opinion, major drivers behind BM&'s recent rally are the promising efficacy of Iza-Bren in triple-negative breast cancer, as well as strong demand for Opdivo Qvantig and Breyanzi.Also, Bristol-Myers Squibb raised its 2026 diluted EPS guidance from $6.05-$6.35 to $6.75-$7.In this article, I explain why the BMY stock risk/reward profile remains attractive after its Q2 results. recep-bg/E+ via Getty Images
Two hours ago, Bristol-Myers Squibb Company (BMY) released its Q2 earnings.
So, in Q2, its revenue was $12.97 billion, up 12.9% quarter-over-quarter.
Meanwhile, BMS's non-GAAP EPS was up 39.7% year-over-year and 29.1% QoQ to $2.04. It also beat my "base case" scenario
3.5K Followers
Analyst’s Disclosure: I/we have a beneficial long position in the shares of LEGN either through stock ownership, options, or other derivatives. I wrote this article myself, and it expresses my own opinions. I am not receiving compensation for it (other than from Seeking Alpha). I have no business relationship with any company whose stock is mentioned in this article.
Seeking Alpha's Disclosure: Past performance is no guarantee of future results. No recommendation or advice is being given as to whether any investment is suitable for a particular investor. Any views or opinions expressed above may not reflect those of Seeking Alpha as a whole. Seeking Alpha is not a licensed securities dealer, broker or US investment adviser or investment bank. Our analysts are third party authors that include both professional investors and individual investors who may not be licensed or certified by any institute or regulatory body.
Bristol Myers zvýšila svůj celoroční výhled tržeb i zisku po výsledcích za 2. čtvrtletí nad odhady, tažených silným prodejem Eliquis a novějších léků. Eliquis za čtvrtletí vzrostl o 22 % na 4,48 miliardy USD.
Test tubes are seen in front of a displayed Bristol Myers Squibb logo in this illustration taken, May 21, 2021. REUTERS/Dado Ruvic/Illustration/File Photo Purchase Licensing Rights, opens new tab
CompaniesJuly 30 (Reuters) - Bristol Myers Squibb (BMY.N), opens new tab raised its full-year revenue and profit forecast on Thursday after reporting second-quarter results that came in well ahead of Wall Street estimates, driven by strong sales of blood thinner Eliquis and newer drugs like heart medicine Camzyos and anemia treatment Reblozyl.
The U.S. drugmaker reported second-quarter revenue of $12.97 billion, up 6% from a year earlier and above analysts' average estimate of $11.75 billion, according to LSEG data. Adjusted earnings were $2.04 per share, topping expectations of $1.59 per share.
Keep up with the latest medical breakthroughs and healthcare trends with the Reuters Health Rounds newsletter. Sign up here.
The company raised its full-year revenue forecast to $49 billion to $50 billion from its previous range of $46 billion to $47.5 billion. Bristol Myers now sees adjusted 2026 earnings of $6.75 to $7.00 a share, up from its prior view of $6.05 to $6.35.
Bristol Myers has been working to offset sales declines from older medicines facing generic competition, particularly blood cancer treatment Revlimid, once its top-selling drug. Revlimid sales fell 49% to $425 million in the quarter.
"Our growth portfolio grew 15% in Q2," Chief Commercialization Officer Adam Lenkowsky said in an interview. "We now have nine products that were growing double digits, and these are all medicines that are early in their life cycle."
Reblozyl sales of $735 million topped analysts' expectations of about $664 million. Camzyos generated $416 million versus expectations of $365 million, while cancer cell therapy Breyanzi brought in $484 million compared with Wall Street estimates of $422 million.
The company raised its Eliquis sales forecast for the year to growth of 20% to 25%, from a prior projection of 10% to 15%. Sales of Eliquis, which Bristol Myers shares with Pfizer (PFE.N), opens new tab, were $4.48 billion in the quarter, up 22% and above analysts' estimates of $4.06 billion.
Eliquis' share of new U.S. prescriptions is approaching 80%, Lenkowsky said.
The company had raised its Eliquis forecast in February, saying a price cut would allow it to avoid penalties imposed by the U.S. government's Medicare health insurance program.
Sales of blockbuster cancer immunotherapy Opdivo fell 3% to $2.49 billion, slightly below expectations.
Bristol Myers is focused on converting patients to Opdivo Qvantig, a subcutaneous version of the immunotherapy, Lenkowsky said, adding that conversion from intravenous Opdivo is approaching 15%.
Qvantig generated $261 million in quarterly revenue, above analysts' estimates of $215 million.
Combined sales of Opdivo and Qvantig are growing at a mid-single-digit rate, the company said.
Reporting by Michael Erman in New Jersey; Editing by Bill Berkrot
Our Standards: The Thomson Reuters Trust Principles., opens new tab
Wall Street analysts forecast that Bristol Myers Squibb (BMY - Free Report) will report quarterly earnings of $1.59 per share in its upcoming release, pointing to a year-over-year increase of 8.9%. It is anticipated that revenues will amount to $11.67 billion, exhibiting a decrease of 4.9% compared to the year-ago quarter.
The consensus EPS estimate for the quarter has undergone an upward revision of 1.1% in the past 30 days, bringing it to its present level. This represents how the covering analysts, as a whole, have reassessed their initial estimates during this timeframe.
Ahead of a company's earnings disclosure, it is crucial to give due consideration to changes in earnings estimates. These revisions serve as a noteworthy factor in predicting potential investor reactions to the stock. Numerous empirical studies consistently demonstrate a strong relationship between trends in earnings estimate revision and the short-term price performance of a stock.
While it's common for investors to rely on consensus earnings and revenue estimates for assessing how the business may have performed during the quarter, exploring analysts' forecasts for key metrics can yield valuable insights.
Bearing this in mind, let's now explore the average estimates of specific Bristol Myers metrics that are commonly monitored and projected by Wall Street analysts.
It is projected by analysts that the 'Net Sales- Zeposia' will reach $156.09 million. The estimate suggests a change of +4.1% year over year.
Analysts predict that the 'Net Sales- Orencia' will reach $940.44 million. The estimate indicates a year-over-year change of -2.3%.
The consensus estimate for 'Net Sales- Eliquis' stands at $4.00 billion. The estimate points to a change of +8.7% from the year-ago quarter.
Analysts' assessment points toward 'Net Sales- Yervoy' reaching $725.82 million. The estimate indicates a change of -0.3% from the prior-year quarter.
The consensus among analysts is that 'Net Sales- Abraxane- U.S.' will reach $11.33 million. The estimate indicates a year-over-year change of -65.7%.
According to the collective judgment of analysts, 'Net Sales- Opdivo- U.S.' should come in at $1.33 billion. The estimate suggests a change of -11.6% year over year.
Based on the collective assessment of analysts, 'Net Sales- Pomalyst/Imnovid- U.S.' should arrive at $157.65 million. The estimate points to a change of -73% from the year-ago quarter.
Analysts forecast 'Net Sales- Pomalyst/Imnovid- International' to reach $52.98 million. The estimate suggests a change of -57.3% year over year.
The combined assessment of analysts suggests that 'Net Sales- Revlimid- U.S.' will likely reach $116.34 million. The estimate suggests a change of -84.1% year over year.
Analysts expect 'Net Sales- Revlimid- International' to come in at $58.84 million. The estimate points to a change of -44.5% from the year-ago quarter.
The average prediction of analysts places 'Net Sales- Reblozyl- U.S.' at $516.22 million. The estimate points to a change of +14% from the year-ago quarter.
The collective assessment of analysts points to an estimated 'Net Sales- Reblozyl- International' of $138.36 million. The estimate indicates a change of +21.4% from the prior-year quarter.
View all Key Company Metrics for Bristol Myers here>>>
Shares of Bristol Myers have demonstrated returns of +8% over the past month compared to the Zacks S&P 500 composite's +0.8% change. With a Zacks Rank #3 (Hold), BMY is expected to mirror the overall market performance in the near future. You can see the complete list of today's Zacks Rank #1 (Strong Buy) stocks here >>>> .
Bristol Myers Squibb má výnos z dividendy 4,1 % a podle odhadů ji letos pokryjí zisk 2,5× a volný cash flow více než dvojnásobně. Rizikem je patentový útes: Eliquis a Opdivo mohou čelit generikům do roku 2028.
When dividend yields start to creep up, it's worth taking a closer look for any potential warning signs. Bristol Myers Squibb (BMY +0.94%) is a leading pharmaceutical company and has been a high-yield dividend stock for some time. Shares have averaged a dividend yield of 3.4% over the past decade.
However, that yield has been abnormally high for most of the past two years. The stock yields 4.1% today, and it's been as high as 6% over the past 24 months. Is the dividend simply too good to be true at this point?
My take is that the dividend is fine right now, but that you'll also need to watch out for potential hurdles as key drugs lose patent exclusivity over the next few years.
Image source: The Motley Fool.
The financials back up Bristol Myers Squibb's juicy dividend for now There's a famous expression that money talks. Examining the financials is the best way to check whether a company can actually afford its dividend. Bristol Myers Squibb pays a quarterly dividend totaling $2.52 per share for the year. Wall Street analysts estimate that it will earn $6.34 per share this year, enough to cover the dividend 2.5 times over.
If you're not satisfied, you can double-check this by looking at free cash flow, since dividends are technically a cash expense. Bristol Myers Squibb has generated $5.83 per share in free cash flow over the past year, covering the dividend more than twice over. From a numbers standpoint, the company can genuinely afford its dividend, and quite easily. The near-term risk of a cut seems pretty low.
Today's Change
(
0.94
%) $
0.58
Current Price
$
62.09
Keep an eye on how the drugmaker navigates a looming patent cliff The coast isn't quite clear, though. Patents for some of Bristol Myers Squibb's top-selling drugs will expire over the next few years. As those patents expire, generics will flood the market at low prices, and sales for those branded drugs will crater. It's a normal part of a drug's lifecycle and happens all the time in the pharmaceutical business.
This situation is called a patent cliff, and Bristol Myers Squibb faces a pretty steep one. Eliquis and Opdivo could both face generic competition by 2028 -- and the two drugs combined for over $6.1 billion in sales last year, roughly half of the company's total revenue. Not all is lost, though: Even after the patents expire, branded sales won't go to zero overnight. Additionally, the company has a strong pipeline, and its growth portfolio of newer drugs is steadily taking the baton.
The market perceives Bristol Myers Squibb as a riskier stock these days, and that's not necessarily wrong. Fortunately, the dividend has lots of breathing room, and there's growth from newer drugs on the way. I could see management scaling back dividend growth, perhaps issuing smaller raises to conserve cash while the company navigates these sensitive years. But barring catastrophic failure, I think you can reasonably trust the stock's 4.1% yield now and in the future.
Bessemer Group Inc. boosted its holdings in Bristol Myers Squibb Company (NYSE:BMY – Free Report) by 19.6% in the first quarter, according to the company in its most recent Form 13F filing with the SEC. The institutional investor owned 70,632 shares of the biopharmaceutical company’s stock after purchasing an additional 11,584 shares during the quarter. Bessemer Group Inc.’s holdings in Bristol Myers Squibb were worth $4,283,000 at the end of the most recent quarter.
A number of other institutional investors and hedge funds have also recently modified their holdings of the business. Swiss RE Ltd. acquired a new position in shares of Bristol Myers Squibb during the 4th quarter valued at $25,000. Darwin Wealth Management LLC acquired a new stake in Bristol Myers Squibb in the second quarter worth $25,000. Physician Wealth Advisors Inc. grew its holdings in Bristol Myers Squibb by 73.5% in the fourth quarter. Physician Wealth Advisors Inc. now owns 477 shares of the biopharmaceutical company’s stock worth $26,000 after purchasing an additional 202 shares during the period. Bayban bought a new stake in Bristol Myers Squibb in the fourth quarter valued at $31,000. Finally, EQ Wealth Advisors LLC bought a new stake in Bristol Myers Squibb in the fourth quarter valued at $32,000. 76.41% of the stock is currently owned by institutional investors.
Analysts Set New Price Targets BMY has been the topic of a number of research analyst reports. Wall Street Zen raised shares of Bristol Myers Squibb from a “buy” rating to a “strong-buy” rating in a research report on Saturday, June 27th. Bank of America decreased their target price on Bristol Myers Squibb from $67.00 to $66.00 and set a “buy” rating for the company in a research report on Friday, July 10th. Citigroup reiterated a “neutral” rating on shares of Bristol Myers Squibb in a report on Friday, May 1st. Guggenheim reissued a “buy” rating and issued a $72.00 price objective on shares of Bristol Myers Squibb in a research note on Wednesday, April 8th. Finally, Weiss Ratings downgraded Bristol Myers Squibb from a “hold (c+)” rating to a “hold (c)” rating in a report on Thursday. Eight equities research analysts have rated the stock with a Buy rating, ten have assigned a Hold rating and one has issued a Sell rating to the stock. According to data from MarketBeat.com, the stock currently has an average rating of “Hold” and a consensus target price of $61.25.
Get Our Latest Stock Analysis on BMY
More Bristol Myers Squibb News Here are the key news stories impacting Bristol Myers Squibb this week:
Positive Sentiment: Bristol Myers Squibb expanded its NVIDIA partnership and plans to deploy a DGX SuperPOD based on Vera Rubin systems, which the company says will become the most powerful AI factory in life sciences and should enhance drug discovery and development efficiency. Bristol Myers Expands NVIDIA Partnership to Build Top Life Sciences AI Supercomputer Positive Sentiment: The company also said it will be the first life sciences firm to buy Nvidia’s latest DGX SuperPOD system, signaling an aggressive investment in AI infrastructure that could strengthen Bristol Myers’ competitive position in future drug research. Bristol Myers buys Nvidia’s latest AI computing system for drug research Neutral Sentiment: A Reuters report repeated the AI-infrastructure news, reinforcing the strategic nature of the announcement but adding no materially new information for investors. Bristol Myers buys Nvidia’s latest AI computing system for drug research Neutral Sentiment: Bristol Myers was mentioned in a broader article about cancer-drug competition and next-generation therapies, but the piece mainly discussed the market landscape rather than any company-specific development. Merck’s Keytruda Faces a Patent Cliff. These New Cancer Drugs Could Take Over. Negative Sentiment: Healthcare stocks fell late Monday afternoon, which may be creating a modest drag on BMY and offsetting some of the optimism from the NVIDIA partnership news. Sector Update: Healthcare Stocks Fall Late Afternoon Bristol Myers Squibb Stock Down 0.7% Shares of NYSE BMY opened at $60.30 on Tuesday. The company has a debt-to-equity ratio of 2.10, a current ratio of 1.42 and a quick ratio of 1.28. The company has a 50-day moving average price of $57.11 and a 200-day moving average price of $57.85. The stock has a market capitalization of $123.14 billion, a P/E ratio of 16.94, a P/E/G ratio of 0.17 and a beta of 0.23. Bristol Myers Squibb Company has a 1 year low of $42.52 and a 1 year high of $62.89.
Bristol Myers Squibb (NYSE:BMY – Get Free Report) last posted its earnings results on Thursday, April 30th. The biopharmaceutical company reported $1.58 earnings per share for the quarter, topping analysts’ consensus estimates of $1.42 by $0.16. The company had revenue of $11.49 billion for the quarter, compared to analyst estimates of $10.93 billion. Bristol Myers Squibb had a net margin of 15.01% and a return on equity of 64.87%. The firm’s revenue was up 2.6% compared to the same quarter last year. During the same quarter in the prior year, the business posted $1.80 EPS. Bristol Myers Squibb has set its FY 2026 guidance at 6.050-6.350 EPS. On average, equities research analysts forecast that Bristol Myers Squibb Company will post 6.34 EPS for the current fiscal year.
Bristol Myers Squibb Announces Dividend The business also recently announced a quarterly dividend, which will be paid on Monday, August 3rd. Stockholders of record on Thursday, July 2nd will be issued a $0.63 dividend. This represents a $2.52 dividend on an annualized basis and a dividend yield of 4.2%. The ex-dividend date is Thursday, July 2nd. Bristol Myers Squibb’s dividend payout ratio (DPR) is currently 70.79%.
About Bristol Myers Squibb (Free Report)
Bristol Myers Squibb is a global biopharmaceutical company headquartered in Princeton, New Jersey, focused on discovering, developing and delivering medicines for serious diseases. The company’s core activities include research and development, clinical development, manufacturing and commercialization of prescription pharmaceuticals across multiple therapeutic areas. BMS concentrates on advancing therapies in oncology, hematology, immunology, cardiovascular disease and specialty areas through both small molecules and biologics.
BMS’s marketed portfolio and late‑stage pipeline reflect a strong emphasis on cancer and immune‑mediated conditions.
Further Reading Five stocks we like better than Bristol Myers Squibb The Ugliest Stocks in the Market Just Got a Very Expensive Vote of Confidence Is Domino’s Stock Serving Up a Buying Opportunity? A $1T Black Hole: SpaceX Eyes Pentagon AI to Break Free Why Gold Miners Could Be the Market’s Biggest Comeback Story
Receive News & Ratings for Bristol Myers Squibb Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Bristol Myers Squibb and related companies with MarketBeat.com's FREE daily email newsletter.
« PREVIOUS HEADLINEBessemer Group Inc. Boosts Stock Holdings in Enphase Energy, Inc. $ENPH
NEXT HEADLINE »Fifth Third Bancorp Acquires Shares of 75,857 Franklin FTSE Japan ETF $FLJP
Bristol Myers Squibb pořizuje nejnovější výpočetní systém Nvidia DGX SuperPOD na bázi Vera Rubin pro využití AI ve výzkumu a vývoji léků. Firma bude první společností z oblasti life sciences s tímto systémem.
Item 1 of 2 Test tubes are seen in front of a displayed Bristol Myers Squibb logo in this illustration taken, May 21, 2021. REUTERS/Dado Ruvic/Illustration
[1/2]Test tubes are seen in front of a displayed Bristol Myers Squibb logo in this illustration taken, May 21, 2021. REUTERS/Dado Ruvic/Illustration Purchase Licensing Rights, opens new tab
CompaniesNEW YORK, July 20 (Reuters) - Bristol Myers Squibb (BMY.N), opens new tab said on Monday it is buying the latest-generation computing system from chip company Nvidia (NVDA.O), opens new tab to support its use of artificial intelligence across its drug discovery and development operations.
The drugmaker said it will be the first life sciences company to buy an Nvidia DGX SuperPOD based on its Vera Rubin systems. The chipmaker unveiled its Vera Rubin architecture earlier this year as the successor to its current generation of AI computing systems.
Jumpstart your morning with the latest legal news delivered straight to your inbox from The Daily Docket newsletter. Sign up here.
Financial terms of the Bristol Myers investment were not disclosed. It builds on a smaller SuperPOD system the drugmaker bought from Nvidia, which is around two or three generations behind Vera Rubin, BMS executives said in an interview.
Pharmaceutical companies are increasingly investing in AI infrastructure to try to identify drug targets faster and improve the odds that experimental drugs succeed in clinical trials.
Robert Plenge, chief research officer at Bristol Myers, said the new capabilities would allow the company to cycle through many more potential drug candidates early in the drug development cycle.
"Maybe before we could do 10 and now we can do dozens," he said.
Plenge also said that the company is already using AI tools to cut the time to make medicines to test in trials by 20% to 30%. That could even reach 50% in coming years, he said.
He said one experimental sickle cell disease treatment currently in early clinical development by the company would likely not have been discovered if not for AI-enabled research.
Greg Meyers, the company's chief digital and technology officer, said the investment was driven in part by rapidly growing computing demands as Bristol deploys larger AI models across its research organization. It uses AI in all of its small-molecule and most of its large-molecule programs.
He also said the new system will be more energy efficient.
"When you host these things, you have to pay an electric bill," Meyers said. "Think of it as 10 times more compute capacity per watt spent ... Electricity is not getting cheaper."
Reporting by Michael Erman; editing by David Gaffen
Our Standards: The Thomson Reuters Trust Principles., opens new tab
Trumpova administrativa uzavřela dobrovolné dohody o cenách léků s 17 z největších farmaceutických výrobců na světě, včetně Pfizer, AbbVie a Bristol Myers Squibb. Dohody mají sladit ceny vybraných léků s cenami ve vyspělých zemích a rozšířit slevy přes TrumpRx.
Drug pricing has been hanging over the pharmaceutical industry for years, and the Trump administration didn't eliminate that pressure. It did, however, pursue voluntary pricing agreements with many of the industry's largest drugmakers. Since late 2025, the Trump administration has reached voluntary most-favored-nation (MFN) pricing agreements with 17 of the world's largest pharmaceutical manufacturers, including Pfizer (PFE +1.32%), AbbVie (ABBV 0.03%), and Bristol Myers Squibb (BMY +3.06%).
These agreements generally align prices for certain drugs with those paid in comparable developed countries, expand discounted direct-to-consumer purchasing through the TrumpRx platform, and provide MFN pricing for certain Medicaid purchases. So the obvious question is: Will lower drug prices automatically translate into lower profits? Let's take a closer look and find out.
Image source: Getty Images.
Pfizer moved first Pfizer became the first major pharmaceutical company to reach an agreement with the administration, offering discounts on more than 30 branded medicines. Management has framed the initiative as a way to improve affordability while preserving incentives for pharmaceutical innovation.
Now, that might appear negative for revenue; lower prices generally mean the company makes less per prescription. But Pfizer has another problem that arguably matters more: It needs to replace revenue lost from the decline of its COVID-19 products. The company's own projections assumes an additional $1.5 billion decline in COVID-related revenue, separate from revenue pressure caused by patent expirations.
Today's Change
(
1.32
%) $
0.32
Current Price
$
24.49
That said, Pfizer is investing heavily in oncology, vaccines, and obesity treatments, while pursuing additional cost reductions. A clearer pricing framework, even if it results in somewhat lower prices, could reduce regulatory uncertainty and help management make longer-term capital allocation decisions.
AbbVie has more flexibility Compared to Pfizer, AbbVie enters this environment from a position of strength. You see, Humira, once the world's best-selling drug, has already faced years of biosimilar competition. Management spent considerable time preparing for that transition with newer immunology drugs Skyrizi and Rinvoq, which now drive much of the company's growth.
Those products continue posting strong double-digit percentage sales increases, giving AbbVie a much more diversified business than it had just a few years ago. Skyrizi has become one of its most important growth drivers, generating nearly $4.5 billion in first-quarter 2026 sales, up 31% from a year earlier. Rinvoq continues delivering strong growth across multiple autoimmune diseases, including rheumatoid arthritis, Crohn's disease, ulcerative colitis, and atopic dermatitis. In the first quarter, Rinvoq revenue increased 23% year over year to roughly $2.1 billion, making it one of AbbVie's fastest-growing blockbuster medicines.
Today's Change
(
-0.03
%) $
-0.08
Current Price
$
248.00
Together, the two therapies are generating billions of dollars in annual revenue and are expected to more than offset the decline in Humira sales over the next several years. That transition leaves AbbVie less dependent on a single blockbuster drug and better positioned to absorb future pricing pressure.
Bristol Myers Squibb needs to fill a gap Bristol Myers Squibb faces a different challenge, as drug pricing isn't its only issue. Several of its top-selling products are already approaching (or facing) patent expirations, meaning they will be hit with competition from cheaper imitations. Revlimid has been steadily losing revenue as generic competition expands, while Eliquis, its blockbuster blood thinner co-marketed with Pfizer, is expected to face similar pressure later this decade.
Together, those products have generated tens of billions of dollars in annual sales, leaving Bristol Myers with a significant revenue gap to fill. Management has responded by launching newer medicines, expanding its late-stage pipeline, and pursuing acquisitions to strengthen its oncology, immunology, and cardiovascular portfolios. Whether those newer therapies can replace the revenue lost from aging blockbusters will likely have a much greater impact on long-term earnings than modest changes in drug pricing.
Today's Change
(
3.06
%) $
1.76
Current Price
$
59.34
The industry appears to be adapting So far, it seems as though the industry is adapting calmly, without any major red flags. And rather than mounting broad public opposition, many large pharmaceutical companies have chosen to negotiate. By April 2026, agreements included manufacturers that represent roughly 86% of the branded U.S. pharmaceutical market.
This is mostly the result of investor behavior. It's no secret that investors generally dislike regulatory uncertainty more than they dislike modest reductions in profitability. And the agreements may also provide other benefits, including tariff relief for participating manufacturers that expand U.S. production under separate administration policies. To put it simply: Complying, rather than fighting, was the most reasonable and sound strategy.
To be sure, drug pricing is becoming a larger factor in pharmaceutical investing, but it shouldn't become the only factor. Pipeline quality, research productivity, acquisitions, and manufacturing execution will continue driving long-term shareholder returns.
For Pfizer, the priority remains rebuilding growth beyond COVID products. For AbbVie, it's sustaining momentum from Skyrizi and Rinvoq. For Bristol Myers, success depends largely on replacing aging blockbuster products with next-generation therapies.
The new pricing agreements certainly change the industry's operating environment. But they don't eliminate what has always mattered most in pharmaceuticals: Companies that consistently develop valuable new medicines tend to create the most value for shareholders over time.
FDA přijala žádost Bristol Myers Squibb o mezigdomid pro relabující nebo refrakterní mnohočetný myelom. Podání podporují pozitivní výsledky fáze 3 studie SUCCESSOR-2, kde medián přežití bez progrese dosáhl 18,0 měsíce oproti 8,3 měsíce.
The agency assigned a Prescription Drug User Fee Act target action date of May 13, 2027, with the filing supported by positive Phase 3 SUCCESSOR-2 trial results.
• Bristol-Myers Squibb stock is building positive momentum. Why are BMY shares climbing?
FDA Accepts Mezigdomide ApplicationMezigdomide is an oral cereblon E3 ligase modulator (CELMoD), being developed to treat multiple myeloma.
The NDA seeks approval of the combination regimen, known as MeziKd, for patients with relapsed or refractory disease.
He noted Bristol Myers Squibb now has two separate agents under FDA review for relapsed or refractory multiple myeloma, adding that the company continues to advance its CELMoD pipeline across blood cancers and solid tumors.
Phase 3 SUCCESSOR-2 Trial ResultsThe NDA is based on data from the Phase 3 SUCCESSOR-2 study, which evaluated MeziKd against the standard regimen of carfilzomib and dexamethasone (Kd).
According to the company, the combination delivered a clinically meaningful and statistically significant improvement in progression-free survival.
Median progression-free survival reached 18.0 months compared with 8.3 months for the control arm, translating to a 52% reduction in the risk of disease progression or death (HR: 0.48).
The benefit was observed in patients with relapsed or refractory multiple myeloma, including those receiving treatment after a prior anti-CD38 monoclonal antibody and lenalidomide.
Safety Profile and Next StepsBristol Myers Squibb said the safety profile of MeziKd was consistent with findings from previous mezigdomide studies and aligned with the known safety profiles of the individual medicines included in the regimen.
The company also acknowledged the patients and investigators who participated in the Phase 3 SUCCESSOR-2 trial.
BMY Stock Price Activity: Bristol-Myers Squibb shares were up 2.29% at $58.90 at the time of publication on Monday, according to Benzinga Pro data.
Photo: Shutterstock
Market News and Data brought to you by Benzinga APIs
Bristol Myers Squibb má dividendový výnos 4,3 % a podle článku je zatím bezpečný, protože zisk pokrývá dividendu. Rizikem zůstává patentový útes v roce 2028, kdy Eliquis a Opdivo ztrácejí patentovou exkluzivitu.
Bristol Myers Squibb (BMY +3.98%) belongs to an elite group. Only two other large-cap healthcare stocks offer higher dividend yields. Bristol Myers Squibb's juicy yield of 4.3% is absolutely grabbing the attention of many income investors.
The drugmaker has paid a dividend for an impressive 94 consecutive years. Bristol Myers Squibb has increased its dividend for 17 straight years. But is its dividend safe now? Here's what investors need to know.
Image source: Getty Images.
The coverage, the cliff, and the catalysts Let's start with some good news. Bristol Myers Squibb's dividend payout ratio currently stands at 70%. While a lower ratio is preferable, the pharma giant's earnings are more than sufficient to cover its dividend right now.
Sure, Bristol Myers Squibb didn't generate enough free cash flow in the first quarter of 2026 to fund its dividend program. However, this reflected the negative impact of lower Eliquis pricing that should be largely offset later this year by lower rebate payments.
The bad news for Bristol Myers Squibb's dividend, though, is the company's looming patent cliff. Blockbuster drugs Eliquis and Opdivo lose patent exclusivity in 2028. These two products generated roughly half of Bristol Myers Squibb's total revenue last year.
However, the patent cliff is only part of the story. Bristol Myers Squibb's growth portfolio now represents the majority of the company's total revenue. Sales for newer products, including cancer immunotherapies Breyanzi and Opdualag, autoimmune disease drug Sotyktu, and schizophrenia therapy Cobenfy, are growing rapidly. The drugmaker's pipeline also features around 50 programs in development, several of which hold the potential to be growth catalysts.
Today's Change
(
3.98
%) $
2.22
Current Price
$
58.03
The verdict My take is that Bristol Myers Squibb's 4.3% dividend yield is safe, at least for the next couple of years. What about beyond that point? I'm cautiously optimistic.
I expect that Bristol Myers Squibb's growth portfolio will generate enough revenue that the company will be able to avoid cutting its dividend later this decade. It wouldn't surprise me, though, if the streak of dividend increases comes to a screeching halt.
That said, it's still possible that the patent cliff could hurt Bristol Myers Squibb worse than I'm anticipating. The drugmaker's debt also totaled $44.5 billion at the end of the first quarter of 2026. That's manageable but coud become problematic if the growth portfolio and pipeline don't deliver as I think they will.
I wouldn't completely rule out a dividend cut in the future. However, I still view this pharma stock as a good pick for income investors over the near term (and potentially over the long term, too).
